

Chronic Lyme Disease and Co-infections: Differential Diagnosis

Walter Berghoff*

Practice of Internal Medicine, Rheinbach, 53359, Germany

Abstract: In Lyme disease concurrent infections frequently occur. The clinical and pathological impact of co-infections was first recognized in the 1990th, *i.e.* approximately ten years after the discovery of Lyme disease. Their pathological synergism can exacerbate Lyme disease or induce similar disease manifestations. Co-infecting agents can be transmitted together with *Borrelia burgdorferi* by tick bite resulting in multiple infections but a fraction of co-infections occur independently of tick bite. Clinically relevant co-infections are caused by Bartonella species, *Yersinia enterocolitica*, *Chlamydomphila pneumoniae*, *Chlamydia trachomatis*, and *Mycoplasma pneumoniae*. In contrast to the USA, human granulocytic anaplasmosis (HGA) and babesiosis are not of major importance in Europe. Infections caused by these pathogens in patients not infected by *Borrelia burgdorferi* can result in clinical symptoms similar to those occurring in Lyme disease. This applies particularly to infections caused by *Bartonella henselae*, *Yersinia enterocolitica*, and *Mycoplasma pneumoniae*. *Chlamydia trachomatis* primarily causes polyarthrititis. *Chlamydomphila pneumoniae* not only causes arthritis but also affects the nervous system and the heart, which renders the differential diagnosis difficult. The diagnosis is even more complex when co-infections occur in association with Lyme disease. Treatment recommendations are based on individual expert opinions. In antibiotic therapy, the use of third generation cephalosporins should only be considered in cases of Lyme disease. The same applies to carbapenems, which however are used occasionally in infections caused by *Yersinia enterocolitica*. For the remaining infections predominantly tetracyclines and macrolides are used. Quinolones are for alternative treatment, particularly gemifloxacin. For *Bartonella henselae*, *Chlamydia trachomatis*, and *Chlamydomphila pneumoniae* the combination with rifampicin is recommended. Erythromycin is the drug of choice for *Campylobacter jejuni*.

Keywords: Bartonellosis, *Borrelia burgdorferi*, *Chlamydomphila pneumoniae*, *Chlamydia trachomatis*, co-infection, Lyme disease, *Mycoplasma pneumoniae*, treatment, *Yersinia enterocolitica*.

INTRODUCTION

In Lyme disease, other infections, whose pathological synergism exacerbate the disease or induce similar clinical manifestations, can exist concurrently. Such concomitant infections are termed co-infections. Co-infections can be transmitted together with *Borrelia burgdorferi* by tick-bite, and result in multiple infection. Part of co-infections is independent of tick-bite.

The goal of this review was to summarize the more important co-infections completed with some personal experiences and with a short summary on reactive arthritis. Because of the similarity of the clinical symptoms of tularemia, Q fever, parvovirus B19 and *Campylobacter jejuni* infections to those of Lyme disease a short summary of these infections are also included.

RELEVANT CO-INFECTIONS IN LYME DISEASE

Co-infections can exacerbate Lyme disease through immune system modulation and are considered to be the major cause for resistance to therapy [1-17]. The importance of

co-infections in the disease process, *i.e.* their pathogenicity compared to Lyme disease, has not been clarified. In cases with double or multiple infections, to determine which infection predominates in the pathological process is difficult. There are substantial overlaps between the clinical symptoms caused by co-infections and Lyme disease. Consequently, an unequivocal assignment of the manifestations of the disease to existing infections might be difficult. The diagnostic difficulties of Lyme disease and co-infections always concern chronic Lyme disease (late Lyme disease, stage III). The synergic-pathological mechanism requires that co-infections are also present in chronic persistent form. Anamnestic consideration of the acute form of co-infections may be helpful to recognize their persistence in the chronic stage.

For the majority of co-infections, as for Lyme disease, laboratory diagnostic tests for indirect pathogen detection, including serological tests and lymphocyte transformation test (LTT, syn. LPT (lymphocyte proliferation test)) are available. Previous infection can be confirmed with serological tests, but a positive serological finding is not proof that the infection causes the current illness. It cannot prove the presence of active infection, and in case of seronegativity it cannot exclude it. Only if the occurrence of positive laboratory findings or their deterioration occur in temporal relationship with the disease state and development assumption

*Address correspondence to this author at the Practice of Internal Medicine, Telemannstrasse D, 53359 Rheinbach, Germany;
Tel: + 49 2226 2041; Fax: + 49 2226 2044;
E-mail: dr.w.berghoff@t-online.de

of chronic disease may be justified *e.g.* especially in cases with previous sero-negativity or negative LTT or significantly lower initial values.

The significant co-infections in Lyme disease are caused by various Bartonella species, primarily *Bartonella henselae*, by *Chlamydia trachomatis*, *Chlamydophila pneumoniae*, *Yersinia enterocolitica*, and *Mycoplasma pneumoniae* (Table 1)

CO-INFECTIONS IN LYME DISEASE: OWN EXPERIENCE

The frequency of seropositivity and positive LTT of coinfections was evaluated. The laboratory examinations were done in the Institut für Medizinische Diagnostik (IMD), Berlin, Germany. For details of the methods used see reference [34]. The results are illustrated in Table 2. CD57 NK cells are frequently diminished in chronic Lyme disease, but seldom in cases involving only the so called HGE co-infections. The basic principle is that CD57 NK cells can be

Table 1. Co-infections in Lyme Disease

Disease*	Pathogen	Mode of transmission	Reservoir	IC, EC
Tick-borne co-infections				
HGA (HGE) HME	<i>Anaplasma phagocytophila</i> <i>E. chaffeensis</i>	Ticks <i>Ixodes ricinus</i> (Europe) <i>Ixodes scapularis</i> (USA)	White-footed mouse (HGA) Red deer, human beings (HME)	IC
Bartonellosis	<i>Bartonella henselae</i> (<i>Bartonella quintana</i> , <i>Bartonella bacilliformis</i>) [18-20]	Bite or scratch wounds of dog or cat (saliva, claws); cat fleas; lice (<i>B. quintana</i>) [21, 22], tick bite Others: dust mites, flea bites, flea feces (oral infection), contact with cats, contact with dogs (paws, saliva, lice [21], flies, gadflies, blood transmission, mother-child transmission [23])	Cats [24-27], domestic and wild animals [28]	IC
Rickettsiosis Mediterranean spotted fever	<i>Rickettsia helvetica</i> <i>Rickettsia conorii</i>	Ticks, mites, fleas, lice	Ticks	IC
Tularemia	<i>Francisella tularensis</i>	Mosquitos, gadflies, fleas, lice, mites, oral, inhalation	Various vertebrates	IC
Q fever	<i>Coxiella burnetii</i>	Oral or inhalation	Cattle, milk, human beings	IC
Babesiosis	<i>Babesia microti</i> , <i>Babesia divergens</i> [29,30]	<i>Ixodes ricinus</i> (Europe), <i>Ixodes scapularis</i> (USA) [29, 30], blood transfusions [31], perinatal [32, 33]	Cattle (other vertebrates)	IC
Other co-infections (not tick-borne)				
Mycoplasma infections	<i>Mycoplasma pneumoniae</i>	Droplet infection, humans	Human beings	EC
<i>Chlamydophila pneumoniae</i> infection	<i>Chlamydophila pneumoniae</i>	Droplet infection, person to person	Human beings	IC&EC
<i>Chlamydia trachomatis</i> infection	<i>Chlamydia trachomatis</i>	Sexual contact	Human beings	IC&EC
Yersiniosis	<i>Yersinia enterocolitica</i> <i>Yersinia pseudotuberculosis</i> (USA)	Fecal-oral	Various vertebrates	IC&EC
Parvovirus B19 infection	Human parvovirus B19	Respiratory tract: droplet infection, person to person, during pregnancy, blood transfusion	Human beings	IC
<i>Campylobacter jejuni</i> infection	<i>Campylobacter jejuni</i>	Fecal-oral Game and domestic animals, particularly poultry, animal products, contaminated water	Vertebrates	IC&EC

IC = Intracellular; HGA = : human granulocytic anaplasmosis ; HGE = human granulocytic ehrlichiosis; * = Relevant co-infections are highlighted in bold.

Table 2. Positive Serology and Positive LTT for Co-infections (%) in Patients with Chronic Lyme Disease, N = 108

Pathogen	N	Positive Serology (%)	Positive LTT (%)
<i>Mycoplasma pneumoniae</i>	36	36	Nd
<i>Chlamydomphila pneumoniae</i>	66	62	66
<i>Chlamydia trachomatis</i>	100	5	100
<i>Yersinia enterocolitica</i>	58	58	50
<i>Bartonella henselae</i>	78	78	Nd

LTT = lymphocytic transformation test; Nd = not done, LTT=LPT (lymphocyte proliferation test).

Table 3. Main Disease Manifestations of Bartonellosis

Infected scratch or bite wound (cat, dog) tick bite, loose infestation and other infection (Table 1)
Lymph node swelling (regional or generalized [35])
Persistent fever of unknown origin
Abdominal pains, loss of weight [22]
Various eye disorders [36]
Neuroretinitis [37-39]
Neurological manifestations [40-42]
Encephalopathy (very frequent)
Transverse myelitis
Neuroradiculitis
Cerebellar ataxia
Cerebral seizures [41]
Cerebral infarcts due to vasculitis [41]
CSF: mild mononuclear pleocytosis [40]
EEG pathological
Musculoskeletal complaints [43]
Arthritis
Arthralgias
Myalgias
Tendinitis, chronic course of arthropathies [43,44]
Fatigue [45]

diminished in all chronic infectious diseases, but the phenomenon is observed relatively frequently in chronic LD.

In contrast to the USA, human granulocytic anaplasmosis (HGA) or human granulocytic ehrlichiosis (HGE) and babesiosis are of little importance as co-infections in Europe.

BARTONELLOSIS

Bartonellosis can be expected to have substantial significance as a Lyme disease co-infection. With regard to the health policy aspect, Lyme disease is more important because of its frequency. However, in this context it should be noted that bartonellosis has not been nearly as intensively investigated as Lyme disease. With the increasing develop-

ment of laboratory tests, one may expect that the currently underestimated prevalence of bartonellosis will be more correctly registered in the future. The importance of this disease will also be determined on the basis of its frequency. My own observations also show that the serology for *Bartonella* is frequently positive in patients with chronic Lyme disease.

All facets of the transmission mode of bartonellosis have not yet been clarified. The most important data reported in the scientific literature are summarized in Table 1.

Bartonellosis (caused by *Bartonella henselae* and *Bartonella bacilliformis*) can be associated with a high variety of symptoms (Table 3). The bacterial inflammatory skin infection (scratch or bite location) is in no way obligatory, *i.e.*

Table 4. Symptomatology of Bartonellosis

Infected Scratch or Bite Wounds	
Lymphadenopathy	Frequently cardinal symptom
General symptoms	Fever, fatigue, drowsiness, sleep disorders, obesity, swelling in different parts of the body, weariness, headaches, air hunger, fainting fits
Encephalopathy	Cognitive, disorders, concentration and memory difficulties, blockage of thought processes, dyslexia and dysgraphia
Mental disorder	Depression, irritability, disturbed impulse control, agitation / aggression, panic attacks
Nervous system	Encephalitis, myelitis, neuralgias, muscular asthenia, paresthesias, neuroradiculitis, seizures, cerebral infarction, Guillain-Barré syndrome
Musculoskeletal system	Arthritis, arthralgias, myalgias, tendinitis, osteomyelitis, myospasm
Abdomen	Abdominal pain, hepatopathy (peliosis hepatis, hepatomegaly), splenopathy (peliosis splenitis), hepatic and splenic abscesses
Heart / Thorax	Endocarditis, pneumonia, pleural effusion, myocarditis
Eye	Oculoglandular disorder, conjunctivitis, neuroretinitis, papillitis, optic neuritis, retinochoroiditis, uveitis anterior, intermedia and posterior [76], acute maculopathy, choroiditis
Urogenital system	Bladder disorder, renopathy, genital disorders
Skin	Bacillary angiomatosis, striae, papulre edema (particularly of the feet), acne, occurrence of venous vessels at an unusual location, hyper- or hypopigmented skin, pea-sized pigment spots, Burgundy-colored, thin skin, Lesions of oral mucosa, Morphea, patchy hair loss, loss of eyelashes, change in hair color in hypopigmented areas, diffuse patchy exanthema, signs of hypervascularity, hematoma-like changes, skin lesions with indentation, erythema nodosum
Other	Parotid swelling, phlegmonous abscess in the neck region, septic shock, thrombocytopenic purpura, overproduction of calcitriol
Laboratory findings	Elevated ESR and CRP, hypercalcemia

bartonellosis can also occur without the typical cat scratch disease, which is characterized by infected skin lesion and lymph node swelling. The main manifestations of the disease comprise in addition to infected skin lesion and swollen lymph nodes various multi-organ disorders (e.g. liver, spleen, nervous system, eye) [18-19], cf. Table 3.

Until 1993 only *B. bacilliformis* was known. The different Bartonella subspecies were first described and their pathological significance recognized in 1993 [22].

There are numerous overlaps with Lyme disease in the clinical manifestations of bartonellosis [46]. The laboratory diagnosis for bartonellosis is based on the analysis of blood smear, on the serology, on pathogen detection using culture methods and PCR and on the histopathological investigations. In early stage the laboratory findings show elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level as well as hypercalcemia.

In cases of infection with Bartonella, the blood smear initially shows pathogens on the outer membranes of erythrocytes, and in the further course of the disease the pathogens are increasingly localized intracellularly. In the process, the light colored center of erythrocytes is lost (Fig. 1).

There is no information on the value of serology in the literature. In particular, the question as to whether seronegativity rules out the disease has not been clarified. On the

other hand, as it is the case for many other infectious diseases, a positive serological finding merely proves that an infection took place, but does not indicate active disease.

Detecting Bartonella in culture is difficult, and the sensitivity is very low, therefore this method of investigation is not part of the routine diagnostics. Detection of pathogens using PCR in biopsies appears to be promising [47, 48], but PCR analysis must follow the biopsy nearly immediately [49].

Chronic course of bartonellosis has been described in numerous studies, including in larger population studies [50-54]. The long duration of the disease frequently for several years, and the similar disease manifestations, makes it difficult to distinguish bartonellosis from chronic Lyme disease. Thus, bartonellosis is of great importance in the differential diagnosis of Lyme disease. In this context, attention should be paid to the fact that *Bartonella henselae* has been found in ticks and that transmission of *Bartonella henselae* by ticks to human has been documented by detecting the pathogen in the CSF [55]. Additionally, the prevalence of *Bartonella henselae* in ticks is apparently high; scientific studies determined a prevalence of 40% [56]. According to my own surveys, 78% of the patients with chronic Lyme disease proved to be seropositive for *Bartonella henselae* (Table 2).

Bartonellosis is accompanied by a stimulation of blood vessel formation, inducing vascularized tumors or granu-




Fig. (1). Erythrocytes infected with *Bartonella henselae*. **A.** At an early stage, the microorganism lies outside of the erythrocytes; **B.** With increasing duration of infection, the bacterium is primarily intracellular and erythrocytes lose their light-colored center.

lomas in various regions of the skin (bacillary angiomatosis), in the liver (peliosis hepatis) or in the spleen (peliosis splenitis) [57-59]. These vascular tumors or granulomas exhibit a pathological sprouting of capillaries with hyperplastic and hyperproliferative endothelial cells [60]. In addition to angiomatosis, Bartonellosis also results in various other skin manifestations associated with increased vessel formation [23], therefore the determination of vascular endothelial growth factor (VEGF) in blood could be of diagnostic importance [23].

In all pathogenic Bartonellae (*Bartonella quintana*, *Bartonella henselae*, *Bartonella bacilliformis*) this effect on endothelial cells and on the induction of angiogenesis has been demonstrated. The vascular proliferation was primarily

traced back to three factors [61-67], namely to elevated endothelial cell proliferation, to inhibition of endothelial cell apoptosis and to increased secretion of vasculo-proliferative cytokines. All these studies support the significant role of VEGF in Bartonella-induced endothelial cell proliferation [67].

Bartonellae are localized in erythrocytes and cause the deformation of erythrocyte membrane [68, 69]. The visualization of bartonellae in erythrocytes is used as a diagnostic tool, particularly with regard to the extent of infection [69]. However, irrefutable literature on erythrocyte infestation in chronic bartonellosis does not exist. The diagnostic value of a new method detecting the pathogen by means of cilia in blood smears cannot be assessed yet. The formation of intra-

Table 5. Antibiotic Treatment of Bartonellosis

Antibiotic	Dose / Day	References
Azithromycin	500 mg	[81, 82, 90-96]
Clarithromycin	1000 mg	[89, 91-97]
Telithromycin	800 mg	[89]
Rifampicin	600 mg	[84, 89, 90, 91, 93, 95, 96, 98]
Trimethoprim + sulfamethoxazole	875 / 125 mg 2x daily	[84, 92, 94, 98]
Ciprofloxacin	1000 mg	[84, 89, 92-94, 98]
Doxycycline	400 mg	[86, 89, 90, 91, 94-96]
Minocycline	200-300 mg	[93]
(Other recommendations: erythromycin, roxithromycin, penicillin G, sparfloxacin, chloramphenicol, streptomycin, gentamycin, Augmentin, ticarcillin, cefotaxime, ceftriaxone, meropenem, trimethoprim and sulfamethoxazole. The information in the various publications is very contradictory. This is particularly true for gentamycin. Beta-lactam antibiotics do not act intracellularly and are therefore not suitable for the treatment of bartonellosis (author's comment) [84,85,87,88,90,91,93,94,97,98-102]. There are substantial discrepancies between <i>in vitro</i> findings and <i>in vivo</i> efficacy.		
Duration of treatment (no reliable data basis)	2 weeks	
Acute early phase		
Chronic course	2 - 3 months	

cellular blebs subsequent to the penetration of the organism into endothelial cells has also been showed for *Bartonella quintana*, i.e. a similar process to that observed on *Borrelia burgdorferi* in Lyme disease. *Borrelia burgdorferi* also has a high affinity for endothelial cells, and the development of blebs, particularly in chronic disorders, has been described. In connection with Lyme disease, the intracellular presence of the pathogen and the formation of biologically less active and more resistant forms (cysts, blebs) have been discussed as the cause of the failure of antibiotic treatment. Corresponding Additional parallels have been also found between Lyme disease and bartonellosis [cf. 70-75].

Two additional forms of bartonellosis merit to be noticed namely, the Oroya fever or Verruga peruana and the trench fever. Oroya fever and its recognition as an infectious disease date back to Carrion, who verified that the disease is infectious in a fatal self-test at the end of the 19th century. Trench fever was discovered at the beginning of the 20th century. Its transmission occurs *via* lice [77-79]. In 2002 the pathogen was detected for the first time in erythrocytes; as a result the transmission by lice became plausible [21]. Oroya fever and Verruga peruana are both *Bartonella bacilliformis* infections transmitted by sand flies. The disease occurs in the Andes. The acute form affects tourists who are immunologically naive with respect to *Bartonella bacilliformis*. Without treatment the mortality rate is 40%. To date, the factor, which influences the severe disease course is unknown.

Adequate studies are missing for the treatment of bartonellosis. There is no single treatment approved by the US Food and Drug Administration (FDA), the Center for Disease Control (CDC) or the Infectious Diseases Society of America (IDSA) [23]. This applies particularly for the chronic courses of the disease [80]. The use of the following antibiotics are recommended (Table 5): azithromycin [81,82], rifampicin, ciprofloxacin, trimethoprim combined with sulfamethoxazole, gentamycin [83,84], gentamycin *i.v.* [85], and doxycycline combined with gentamycin [86, 87]. This treatment is based, in part, on expert recommendations [88]. Further Other references are listed in Table 5.

The discrepancy between the *in vitro* findings and the *in vivo* results is set out in various publications [93,97,99, 102,103].

Since *Bartonella henselae* is primarily localized intracellularly *in vivo*, only antibiotics that act intracellularly are used; they are listed in Table 5.

Because instances of non-response and recidivism are not seldom in cases of chronic bartonellosis, long-term antibiotic treatment is recommended [89,99,102-104].

The efficacy of aminoglycosides (particularly gentamycin) is extremely controversially assessed. Publications with a positive assessment [92,94,95,99,102] are in opposition to other contributions, which assess aminoglycosides as ineffective or insufficiently effective [90,91,93].

Chlamydomphila pneumoniae

Chlamydomphila pneumoniae is important in the differential diagnosis of Lyme disease because it can cause nervous system disorders, myocarditis and reactive arthritis.

Chlamydias have special microbiological characteristics. The size of the pathogen is very small compared to other bacteria. Reproduction occurs within host cells and the pathogen is dependent on host cell ATP as it is not capable to produce its own. The pathogen exhibits two phenotypes, the elementary bodies and the reticulate bodies. The elementary bodies can exist extracellularly and represent the infectious form. Reproduction of the elementary bodies is only possible inside of host cells. Host cells phagocytize the elementary bodies, which intracellularly transform into reticulate bodies and undergo division. The elementary bodies are thus infectious, and the reticulate bodies reproductive. Some reticulate bodies can change back into elementary bodies, which are released subsequently to host cell lysis. The released elementary bodies infest then further host cells. Consequently, precondition for an adequate treatment is both the intra- and extracellular efficacy of the antibiotic. This is the case for tetracyclines and macrolides (Table 6).

The primary disease manifestation of *Chlamydomphila pneumoniae* is pneumonia. The incidence is 1% and predominantly affects people older than 65 years [105,106]. The pneumonia is frequently accompanied by infections of the upper respiratory tract (pharyngitis, laryngitis, sinusitis). An initially slight disease expression, extrapulmonary manifestations [107] and a normal leukocyte count indicate atypical pneumonia, suggestive of *Chlamydomphila pneumoniae* infection. Extrapulmonary manifestations include nervous system disorders including Guillain-Baré syndrome and meningoencephalitis, as well as reactive arthritis and myocarditis, which are significant with regard to the differential diagnosis

Table 6. Antibiotic Treatment of *Chlamydomphila pneumoniae*

Antibiotic	Dose / Day
Azithromycin	500 mg
Clarithromycin	1000 mg
Telithromycin	800 mg
Doxycycline	400 mg
Gemifloxacin	320 mg
Rifampicin (in combination with doxycycline or azithromycin)	600 mg
Treatment duration for chronic course (no reliable data basis)	2 - 3 months, if necessary 6 months for so-called reactive arthritis [108]

of Lyme disease or Lyme neuroborreliosis.

The extrapulmonary manifestations frequently extend across a long period of time, *i.e.* through months or years. This also applies to the so-called reactive arthritis, whose differentiation from Lyme disease arthritis is sometimes difficult. Attention should also be paid to Guillain-Barré syndrome, which can last for months, and with a similar manifestation to that observed in Lyme disease. The association with a myocarditis is also similar, whereas meningoen- cephalitis occurs in the acute phase, almost simultaneously with pneumonia.

The chronic course of *Chlamydomphila pneumoniae* infections is documented by several studies [108-114]. A relationship to *Chlamydomphila pneumoniae* was also described in Alzheimer's disease [115]. This finding is of importance with regard to chronic Lyme neuroborreliosis, for which the same associations have been demonstrated [116-119].

The laboratory diagnosis for *Chlamydomphila pneumoniae* includes serology, the lymphocyte transformation test (LTT), and the detection of the microorganism using PCR.

The serological tests have severe inherent limitations. There is a considerable discrepancy between the serological findings, on the one hand, and pathogen detection using PCR, on the other hand [120,121]. A single test for IgG has a low sensitivity [122], whereas the sensitivity is quite good in cases of a definite increase in IgG between the acute phase and the further course of the disease. The diagnostic value of LTT for *Chlamydomphila pneumoniae* has not yet been validated in the literature. The chronic disease course obviously represents a chronic persistent infection. *Chlamydomphila pneumoniae* could be detected both in the synovial fluid and in the liquor using PCR [108-110,113,114].

Antibiotic treatment of *Chlamydomphila pneumoniae* is given in Table 6. The drug of choice is doxycycline; macrolides also exhibit good efficacy, particularly azithromycin; quinolones have a low efficacy [123], however, gemifloxacin has proven to be very effective [124].

Chlamydia trachomatis

The variable microbiological appearance of *Chlamydia*

trachomatis is similar to that of *Chlamydomphila pneumoniae*, described above. That the infectious form of *Chlamydia trachomatis* is present both intra- and extracellularly is decisive with regard to the efficient antibiotic treatment of the disease.

Chlamydia trachomatis is sexually transmitted and causes urogenital infection. The differential diagnostic problem with respect to Lyme disease results primarily from chronic arthritis, which is caused by persistent infection in both diseases. In *Chlamydia trachomatis* infection, this chronic arthritis is assigned to the so-called reactive arthritis even though that in some studies the pathogen was detected in the synovial fluid, which indicates persistent infectious arthritis [125,126]. Arthritis occurs in 1% of the cases with *Chlamydia trachomatis* urethritis. Reiter's triad (arthritis, uveitis, urethritis) occurs in only 0.3% of the affected patients.

The disease can be easily detected by laboratory diagnostic tests in cases of existing urogenital infection. Nucleic acid amplification techniques (NAATs) for urethral smear or urine are available, which are also reliable for asymptomatic patients [127-129]. PCR has also a high sensitivity and specificity [130]. The diagnostic value of the serology and LTT has not yet been validated. Moreover, whether a chronic infection with *Chlamydia trachomatis* can be accompanied by seronegativity, as in Lyme disease, has not been clarified. Seropositivity can provide evidence of a previous infection, but does not allow conclusion with regard to a persistent infection with *Chlamydia trachomatis*. Theoretically, persistent or reproducible pathological LTT indicates prolonged infection, but scientific data for the diagnostic value of LTT are not yet available.

Treatment of *Chlamydia trachomatis* infection is similar to that of *Chlamydomphila pneumoniae* (Table 6). Duration of treatment is 3 months [108]. In case of arthritic Sulfasalazine [131] and treatment by TNF antibodies [132] were also proposed.

***Yersinia enterocolitica* Infection (Yersiniosis)**

The infectious data and symptomatology of yersiniosis are compiled in Tables 1 and 7, respectively. *Yersinia enterocolitica* was already recognized as pathogen as early as the beginning of the 20th century. However, the true signifi-

Table 7. Yersiniosis (*Y. enterocolitica*) Symptomatology

Stages	Symptoms
Early stage	Gradual development of gastroenteritis, pharyngitis, complications due to inflammation of the intestinal wall, mesenteric lymphadenopathy. Excretory for months after abatement of gastroenteritis
Late stage	Articular manifestations: Reactive arthritis in hip, knee, upper ankle, sacroiliac joints, arthralgias, ankylosing spondylitis, rheumatoid arthritis, sacroiliitis Erythema nodosum, iridocyclitis, conjunctivitis, gastrointestinal complaints, abdominal pain, diarrhea, ulcerative colitis, nephritis, insulin-dependent diabetes mellitus, hepatitis (ANA positive, rheumatoid factor positive), myocarditis (rare), central and peripheral nervous system manifestations, multisystem disease Disease progression in stages with intervals of fewer complaints Correlation with thyroiditis Positive LTT Oscillating serological findings (correlation with disease expression)

cance of the pathogen, in particular, under epidemiological aspects was first described in 1995 [133]. Acute illness due to *Yersinia enterocolitica* is subject to registration (according to German law). The pathogen penetrates into the intestinal wall and the mesenteric lymph nodes. Surface proteins and plasmid-bound virulence factors suppress immune system reactions of the host [134-137].

The early stage of yersiniosis is essentially characterized by gradually developing gastroenteritis and pharyngitis and mesenteric lymphadenitis.

In contrast to other bacterial gastroenteritis, *Yersinia enterocolitica* gastroenteritis develops gradually and often becomes stressful or perceivable only after a week [138-140]. Frequently, the infection is associated with pharyngitis because the pathogens remain in the lymphatic tissue of the tonsils and the pharyngeal wall, where they can also be detected by means of smear test. The concurrent occurrence of gastroenteritis with pharyngitis is typical for a yersiniosis [141].

The mean disease duration is approximately two to three weeks, but distinctly longer disease course have been described. The acute illness can be associated with numerous gastrointestinal complications, primarily as a consequence of a severe bacterial inflammation of the intestinal wall [142-144]. In addition, the disease can also affect many non-gastrointestinal organs [142,143,145-148]. The patients frequently remain excretory for months, even when the gastroenteritis has long since abated [139].

Yersiniosis can result in so-called reactive arthritis and is thus an important infectious disease in the differential diagnosis of Lyme disease. Since the disease can also sporadically occur [139] and frequently remains unrecognized, the anamnestic search for the typical manifestations of yersiniosis particularly symptoms of the early phase is of considerable importance.

Differentiation between Lyme disease and yersiniosis is made even more difficult by the fact that both infections can cause multisystem disease. The study by Saebo und Lassen [149], which describe the various disease manifestations in a retrospective study of 458 patients, is of particular importance for the depiction of chronic yersiniosis: chronic persis-

tent arthralgias, ankylosing spondylitis, rheumatoid arthritis, iridocyclitis, chronic abdominal pains, chronic diarrhea, ulcerative colitis, nervous disorders, nephritis, thyroid disorders, insulin-dependent diabetes mellitus, chronic hepatitis, (multisystem diseases) and a substantial reduction of the overall life expectancy. Many of the different relationships were reported in further publications by these authors [150-155]. Studies suggesting a possible direct relationship between *Yersinia* and inflammatory intestinal disorders [155] close the pathophysiological circle between *Yersinia*, inflammatory intestinal disorders and enteropathic arthritides. Despite this, it should be noted that the relationship between *Yersinia* infection and the above-mentioned numerous disease manifestations (except for arthritis) have been inadequately analyzed. This may be due to the fact that the significance of "yersiniosis" as a disease has only been recently recognized.

In the differential diagnosis of yersiniosis with respect to Lyme disease and other co-infections, the importance is primarily based on the manifestation of a so-called reactive arthritis. This arthritis can last for months, and exhibit recurrent and symptom-free intervals in the disease course. The so-called reactive arthritis in yersiniosis can occur alone, but occasionally also in connection with conjunctivitis and urethritis, previously termed Reiter's syndrome [156]. As in *Chlamydia* infections and possibly in bartonellosis, the arthritis is probably the consequence of chronic persistent infection [157, 158].

The so-called reactive arthritis primarily affects the hip, knee and upper ankle joints as well as the sacroiliac joints; occasionally there are additionally chronic pains in the lumbosacral region [159].

In the differential diagnosis of Lyme disease, it is of particular interest that in some studies *Yersinia enterocolitica* was detected in articular effusions in case of the so-called reactive arthritis [157, 158]. Sometimes these arthritides last for many years. In addition, there is a relationship between yersiniosis and thyroiditis. All these (chronic arthritides, multisystem disorders, disease course lasting for years, correlation with regard to thyroiditis) can also be observed in Lyme disease.

The laboratory diagnostics of *Yersinia enterocolitica* infection is based on the seriological findings, on the LTT

Table 8. Antibiotic Treatment of *Yersinia enterocolitica* Infection

Antibiotic	Dose / Day
Ceftriaxone + Gentamycin	2 g + 240 mg
Ciprofloxacin	1000 mg
Trimethoprim and sulfamethoxazole	875 and 125 mg, x 2 daily
Gentamycin	240 mg
Doxycycline	400 mg
Piperacillin	8 g
Entapeneum	1g
Rifampicin (in combination with doxycycline or azithormycin)	600 mg
Treatment duration for chronic course (no reliable data basis)	2 - 3 months, if necessary 6 months for so-called reactive arthritis [108]

findings and on pathogen detection by PCR and culture.

As in Lyme disease, there is often seropositivity in asymptomatic patients. Information on a possible seronegativity in chronic yersiniosis is not available. In the disease course the serological findings can correlate with disease expression [159]. It is not rare that a highly significant pathological *Yersinia* LTT is found in patients whose complaints are primarily consistent with chronic Lyme disease. Positive *Yersinia* LTT could be an indication of chronic persistent infection especially when reproducible.

Pathogen detection is possible, particularly in articular effusion and in lymphatic tissue of the intestine and in early stages of the disease by throat swab. Data on the sensitivity of pathogen detection using PCR or culture methods does not exist in the relevant literature. In *Yersinia*-PCR-positive patients, the serology was positive in 70% and LTT in 50% of the cases analyzed [160]. In the initial detection of *Yersinia enterocolitica* using culture methods, IgA and IgG bands were found in immunoblot assay in patients experiencing a chronic course of the disease. The continuous detection of IgA antibodies was obviously an expression of persistent infection; in this context the pathogens were detected in the intestinal mucosa and in lymphatic tissue. Hence, this was a definitely chronic, persistent *Yersinia enterocolitica* infection [161]. The antibiotic treatment of *Yersinia enterocolitica* infection is presented in Table 8.

Yersiniosis frequently abates within a few weeks so that an antibiotic treatment is not generally recommended. This also applies with regard to excretors. Antibiotics are used only in cases with severe disease courses, in particular with sepsis. *Y. enterocolitica* produces beta-lactamases with the consequence that penicillin, ampicillin and cephalosporins of the first generation are ineffective [162,163]. Resistance to macrolides is also frequent. It is disputed whether early antibiotic treatment (*i.e.* for gastroenteritis) prevents reactive arthritis [164].

The differential diagnosis of chronic yersiniosis vs chronic Lyme disease, is thus extremely difficult because of the overlap of various clinical symptoms. In cases where both infections are present in their chronic form, a differentiation is often impossible.

Mycoplasma pneumoniae Infection

The differential diagnosis between Lyme disease and *Mycoplasma pneumoniae* infection or the recognition of the co-infection by *Mycoplasma pneumoniae* is problematical because both diseases exhibit similar manifestations; this applies to the extrapulmonary manifestations of *Mycoplasma pneumoniae* infection: disorders of the CNS, musculoskeletal system, heart, kidney and eye.

Data related to *Mycoplasma pneumoniae* infection are given in Table 1 and 9. In the foreground is the atypical pneumonia, frequently linked to symptoms of the upper respiratory tract. There are no data available in the literature with respect to the frequency of extrapulmonary manifestations.

Mycoplasma pneumoniae is considered to be the most important pathogen of atypical pneumonia. However, pneumonia only occurs in approximately 3% - 10% of the cases in *Mycoplasma pneumoniae* infection [165]. In most cases, the infection results in a banal bronchitis [165], pharyngitis, rhinitis, earaches, and sinusitis [163].

All the extrapulmonary disease manifestations listed in Table 9 are seldom [166-174]. In patients with arthritis, *Mycoplasma pneumoniae* was detected in the synovial fluid by PCR [171], which is an indication of a direct relationship to infection.

The detection of pathogen in articular effusion and many extrapulmonary manifestations of the disease document the chronic course of the disease in cases with *Mycoplasma pneumoniae* infection. However, precise data on the chronic course of the disease are not available in the literature. In particular, whether a chronic infection, especially with extrapulmonary disease manifestation, can persist with seronegativity is unclear. Seropositivity documents infection, but cannot serve as a proof for chronic persistent *Mycoplasma pneumoniae* infection.

The literature on the relationship between *Mycoplasma pneumoniae* infection and neurological disease manifestations is extensive. The publications primarily refer to neurological complications in pneumonia, *i.e.* the early phase of *Mycoplasma pneumoniae* infection. Neurological manifestations involve both the early phase, *i.e.* the point in time of existing pneumonia due to *Mycoplasma pneumoniae*, and later disease stages. Changes in the region of the brain stem

Table 9. *Mycoplasma pneumoniae* Infection: Symptoms

Pulmonary and related (older people in nursing and old people's homes are frequently affected) Incubation period 3 weeks	Atypical pneumonia (3% - 10% of cases.) bronchitis, pharyngitis, rhinitis, earaches, sinusitis
Extrapulmonary	Maculopapular exanthema, vesicular dermatitis CNS disorders (are rare): encephalitis, meningitis, myelitis, cranial neuropathy, cerebellar ataxia
Gastrointestinal	Hepatitis, pancreatitis
Rheumatic	Arthritis: arthralgias, myalgias, polyarthritis
Cardiac	Cardiac arrhythmias, atrioventricular block, myocarditis
Glomerulonephritis	
Uveitis	

[175, 176], myelitis [177-187], Guillain-Barré syndrome [188-193], encephalitis [185,187,194-200], meningitis [194], polyradiculopathy [178], peripheral facial paresis [201, 202], optical neuritis and hemorrhagic leukoencephalitis [190], peripheral polyneuropathy [194], cranial nerve neuritis [192], radiculitis [192] have been described.

The frequency of neurological symptoms in connection with *Mycoplasma pneumoniae* varies between 1% [203], 1% [204], and 5% [205]. The pathogen has been repeatedly detected by means of culture methods or PCR [182,193,194].

The detection of pathogen in the serum and liquor is considered to be proof that the neurological manifestations are mediated by direct infection and not by immunological responses [193]. However, the connection between *Mycoplasma pneumoniae* and neurological manifestations is not undisputed [203, 206].

Other extrapulmonary manifestations mentioned in the literature include hepatitis, hemolytic anemia, Schönlein-Henoch purpura, disorders of the muscular-skeletal system, of the skin and other organs [179], macula edema [194], bilateral uveitis [207], nephritis [208], arthritis, hepatitis and pericarditis [208].

The laboratory diagnostics for *Mycoplasma pneumoniae* include the serology, which as in most infectious diseases becomes positive after several weeks. Seroconversion is therefore significant for the chronic disease course. Seropositivity substantiates the infection, but not the disease. Whether a chronic infection can also exist in seronegative cases has not yet been scientifically clarified. The LTT for *Mycoplasma pneumoniae* has not yet been validated.

Detection of the pathogen, e.g. in articular effusion by PCR and culture is possible but difficult and has a low sensitivity. Consequently it is not part of the routine diagnostic procedures.

In the antibiotic treatment of *Mycoplasma pneumoniae* the drugs of choice are azithromycin 500 mg/day [209], levofloxacin 500 mg/day [210] and doxycycline 400 mg/day.

Human Granulocytic Anaplasmosis (HGA)

The pathological importance of human monocytic ehrlichiosis (HME) and human granulocytic anaplasmosis (HGA), which is also called human granulocytic ehrlichiosis (HGE), was discovered in 1986 and 1994, respectively [211, 212]. The two infectious diseases resemble each other clinically and with regard to the laboratory findings. The pathogens develop in monocytes (HME) or in granulocytic leukocytes (HGA). Thus, their localization is exclusively intracellular.

The pathogens are transmitted by infected ticks, primarily via *Ixodes scapularis* in the United States and via *Ixodes ricinus* in Europe. The reservoirs are the white-footed mouse for HGA and the red deer and human beings for HME (Table 1). Other modes of transmission are also discussed, including mother-child transmission, blood transfusions, direct contact with infected animals and transmission from person to person [213-219].

In connection with ehrlichiosis or anaplasmosis, two pathogens are to be noted, respectively, namely *Ehrlichia*

chaffeensis [220] and *Anaplasma phagocytophilum* [221]. *E. chaffeensis* infects monocytes and *Anaplasma Phagocytophila* granulocytes.

Ehrlichia chaffeensis is the pathogen of human monocytic ehrlichiosis (HME), a rare infectious disease, which occurs primarily in the USA and in some regions of South America, but practically nowhere else on earth. *Ehrlichia phagocytophila* is the pathogen of human granulocytic anaplasmosis (HGA), another extremely rare disease in the USA with an annual incidence of approximately 10 / 1 million inhabitants [222]. HGA, is an important co-infection of Lyme disease in the USA, but not in Europe.

The pathogen can be simultaneously transmitted with *Borrelia burgdorferi* with the consequence of a double infection. HGA exhibits many symptoms, which also occur in Lyme disease.

Scientific reports on illnesses due to HGA in Europe are rarities [223]. However, studies in Northern Italy showed that 24% of the ticks (*I. ricinus*) were infected by *Ehrlichia chaffeensis* or *Anaplasma phagocytophilum*. Similar findings have been substantiated in the Netherlands and in Poland, whereas in Germany the frequency is approximately 2% [224-229]. In the East Coast of the United States it is much higher and reaches approximately 30% - 40% [230,231].

In Europe, in patients with Lyme disease the seroprevalence for *Anaplasma phagocytophilum* is approximately 10% [232-234]. Similar findings were also obtained in the USA [235]. Since seroprevalence merely expresses the frequency of the infection, but not an ongoing active infection of HGA, no reliable statements about the prevalence of the disease can be made. According to the laws of probability, a concurrent HGA infection in patients with Lyme disease might amount to a few percent at most. There are no data available in the literature on chronic HGA courses. However, subacute and chronic courses are discussed [236, 237].

The incubation period, i.e. the time between tick bite and emergence of acute illness, is approximately one week [238]. In the acute phase clusters of bacteria are located intercellularly (morale) [239].

The clinical symptoms comprise fever, influenza-like symptoms, headache, joint and muscle pains, coughing, CNS disorders, which include meningitis. Such changes occur frequently and are - particularly in cases involving a febrile clinical picture with the above-mentioned symptoms - an indication for HGA. Indications of HGA are the pathological laboratory findings of leukopenia, thrombocytopenia, and elevated transaminases. The pathogen is localized intracellularly. Anemia and elevated creatinine can rarely occur.

The diagnosis of HGA (also as co-infection) is based on the anamnesis, on the clinical symptoms and laboratory findings, including the serological findings [240-243] and the detection of pathogens. The specific antibodies appear two to three weeks after disease onset and persist following the decline of the disease. Therefore, a positive serology does not confirm ongoing infection of HGA. The pathogen is detected in blood smear, which is not often successful; [244-247], or by PCR from whole blood. The detection by PCR was successful in 20% - 80% of the cases analyzed, with a sensitivity of 60% - 80% [248-251].

Doxycycline is the recommended therapy, also for children. Precise literature with regard to an adequate treatment is not available.

BABESIOSIS

Babesiosis, similarly to HGA, is an important co-infection in the USA, but not in Europe. Babesiae are protozoa and result in lysis subsequent to invasion of erythrocytes. Two species of *Babesia* are pathogenetically significant, namely *Babesia microti* and *Babesia divergens* [29,30]. *Babesia microti* is the predominant pathogen in the USA and *Babesia divergens* in Europe [cf. 252]. The transmission of the pathogen occurs primarily *via* ticks, namely *Ixodes ricinus* in Europe and *Ixodes scapularis* in the USA [29,30]. *Babesia microti* has been found as a co-infection in Lyme disease [253-255]. Other modes of transmission are blood transfusions [31] and perinatal infection [32,33]. The reservoir is the cattle and probably other vertebrates (Table 1).

Since 1956 a total of only 30 cases has been reported in Europe. The majority of these patients were splenectomized. The prevalence of *Babesia microti* and *Babesia divergens* in ticks is 10% - 20% in Europe [256-258], and somewhat higher in the U.S.A. [259]. The seroprevalence with regard to *Babesia microti* and *Babesia divergens* is 0% in European patients with Lyme disease [260,261] and thus is in stark contrast with the frequency of the pathogen in ticks.

The situation in the USA is different, where the seroprevalence is approximately 10% - 20% [262-265] where the disease was reported to occur more frequently, in some cases with severe disease courses [266-269]. This difference can obviously be only explained by the fact that *Babesia microti*, the predominant pathogen in the USA, has a much higher virulence than *Babesia divergens*. Thus, Babesiosis does not play a major role in Europe unless the patient contracted the disease in a foreign country, *e.g.* in the USA.

The clinical picture presents as a febrile, influenza-like medical condition with chills, fever, arthralgias, myalgias, and gastrointestinal symptoms. Severe disease courses only occur in non-immunocompetent patients. The diagnosis is based in addition to the anamnesis and the clinical picture, on the serological findings [270,271] and on the detection of the organism. There is a poor correlation between serologic titer and symptomatology [271]. Detection of the pathogen in blood smear is difficult and frequently requires repeated examinations. The sensitivity of the PCR to detect the organism is higher [272].

Treatment is carried out with atovaquone, azithromycin, and clindamycin, if necessary in combination with quinine.

Following assessment of all data available, it seems that babesiosis - due to the dominant European pathogen, *Babesia divergens* - does not represent a major health hazard and thus is of little consequence as a co-infection in Lyme disease.

RICKETTSIOSES

Attention should be directed to the fact that the causative agent of bartonellosis also belongs to the Rickettsia family. In the USA the most important and more frequent rickettsio-

sis is the Rocky Mountain Spotted Fever (RMSF), a potentially fatal, but normally curable disease. The clinical picture is primarily characterized by high fever, pronounced malaise, abdominal complaints, and a generalized exanthema. Occasionally, the disease is also linked with CNS manifestations comprising focal neurological deficits and cerebral seizures.

Various different rickettsioses caused by different Rickettsia subspecies are distinguished worldwide. The transmission generally occurs *via* ticks, but also *via* mites, fleas, and lice (Table 1). Generalized exanthema - the so-called localized eschar (black wound) - as well as fever, headaches and severe muscle pains are typical symptoms of the disease.

The most important rickettsiosis in Europe is the Mediterranean spotted fever caused by *Rickettsia conorii*. The disease primarily affects Southern Europe. Chronic courses have not been described in the literature. In the early stage, it does not represent differential diagnostic difficulty with respect to Lyme disease, because of the endemic conditions and the presence of the typical exanthema. Treatment is performed with doxycycline.

TULAREMIA

Tularemia is caused by the pathogen *Francisella tularensis*. Transmission occurs *via* mosquitoes. The disease reservoir comprises many vertebrates.

The main disease manifestations are fever, headaches, malaise, swollen lymph nodes, pharyngitis, eschar (black wound), emesis, pneumonia and the erythematous papular-ulcerative lesion at the site of the black spot bite (central eschar, "tache noire").

Relapses can occur, but persistent chronic courses have not been described in the relevant literature. Differential diagnostic problem can occasionally occur with regard to early Lyme disease in cases lacking to erythema migrans.

The treatments of choice are tetracyclines and ciprofloxacin. Beta-lactamases are inefficient.

Q FEVER

In contrast to rickettsioses and tularemia, Q fever can exhibit a chronic course. However, there are no significant differential diagnostic problems with regard to Lyme disease. Q fever normally is endemic and as a rule is caused by contact with livestock *via* inhalation or oral transmission of the pathogen, or by person to person contact. Admittedly, *Coxiella burnetii* can also be found in other reservoirs, *e.g.* in ticks (Table 1), but two items are decisive for the diagnosis: the endemic occurrence and the contact with (diseased) livestock and their products (*e.g.* milk products) and other infected patients.

The decisive diagnosis with regard to a possible Q fever is thus the occupational activity or the contact with agriculture and livestock. In sporadic cases the frequent consumption of raw milk or the contact with diseased cattle (abort) can be indication of an infection hazard.

Significant disease manifestations include transitory influenza-like clinical picture, pneumonia and hepatitis. Other manifestations comprise erythema, pericarditis and/or

myocarditis, meningitis, encephalitis [273-275] and myelitis [276, 277].

Q fever can persist for months or years indicative of a chronic course. Chronic endocarditis is the dominant disease manifestation but pericarditis and Guillain-Barré syndrome also occur [278]. The diagnosis is verified by serological tests detecting the presence of specific antibodies.

HUMAN PARVOVIRUS B19 INFECTION

Human parvovirus B19 infection is transmitted by respiratory tract infection (droplet infection) or during pregnancy and blood transfusion (Table 1). Its reservoir is the human being. The disease can exhibit a chronic course of months or years [279]. Whether parvovirus B19 causes chronic myocarditis and cardiomyopathy is a matter of dispute [280-283]. The chronic course is verified by the detection of pathogen in articular effusions, in the myocardium, bone marrow, and blood [279-285]. With regard to Lyme disease, the following differential diagnostic disease manifestations are relevant: persistent or recurrent arthropathy, myocarditis and cardiomyopathy. Fifth disease or erythema infectiosum is a typical skin manifestation of parvovirus B19 infection in children, but does not normally occur in adults. Arthralgias can last for months or years.

Campylobacter jejuni

Campylobacter jejuni is a small Gram-negative bacterium whose pathological significance was recognized around 1980. *Campylobacter jejuni* is among the most frequent pathogens worldwide, causing acute diarrhea. Sources of infection are game and domestic animals, especially poultry, various animal products and contaminated water [286]. The pathogen can persist in a coccoid form, but also in its normal form, for months in unfavorable conditions. It penetrates epithelial cells of the intestine causing their destruction, possibly by means of toxins [287, 288].

The main clinical manifestations of *Campylobacter jejuni* infection are gastroenteritis and abdominal complications in the early phase and reactive arthritis and Guillain-Barré syndrome in the late phase of the disease.

Campylobacter jejuni has differential diagnostic significance due to the late manifestations of the disease, namely due to reactive arthritis and Guillain-Barré syndrome.

Reactive arthritis in *Campylobacter jejuni* infections is seldom with a frequency of about 2.6% [289-292]. In connection with a *Campylobacter jejuni* infection, Guillain-Barré syndrome has an unfavorable prognosis [293]. Its incidence is approximately 1% [294]. Reactive arthritis occurs approximately one to two weeks after gastroenteritis [288] and Guillain-Barré syndrome approximately two months after the onset of infection [295].

Antibiotic treatment reduces the duration of gastroenteritis. The drugs of choice are erythromycin (1500 mg/daily), azithromycin (500 mg daily) and ciprofloxacin (1000 mg daily). Macrolides [296] and quinolones are primarily recommended, but resistance to them can occur [297]. Resistance to trimethoprim und beta-lactamases also exists [298].

Reactive arthritis

The term "reactive arthritis" characterizes arthritides, which bear a relationship to certain infectious diseases. In former times the term "Reiter syndrome" was used in cases of concurrent infection of the urethra and the uvea. Arthritis, urethritis and uveitis were termed the Reiter's triad [299,300]. Pathogens, which can induce reactive arthritis include *Chlamydia trachomatis*, *Chlamydia pneumoniae*, *Yersinia enterocolitica*, Salmonellae, Shigella, *Campylobacter* (usually *Campylobacter jejuni*), *Mycoplasma pneumoniae* and possibly *Clostridium difficile*.

The term "reactive arthritis" is not a defined disease (nosological entity), but rather a concept for the classification of disease relationships with respect to the pathophysiology. The term "reactive arthritis" is problematical. In various infections with reactive arthritis, the pathogens were detected in the synovia and joint fluid. This is true for *Chlamydia pneumoniae* [108-110], *Chlamydia trachomatis* [125,126] and for *Yersinia enterocolitica* [157,158]. The pathogen was also found in the synovia in cases with arthritis in connection with *Mycoplasma pneumoniae* [171].

Reactive arthritis occurs days to weeks after the onset of infection. It predominantly affects the joints of the lower extremities. In cases with disease duration of less than 6 months, the term "acute reactive arthritis" was designated and for those with disease duration of more than 6 months, the term "chronic reactive arthritis" is used.

In 50% of the cases, the joints of the upper extremities are also affected, including the small joints, and the arthritis can be accompanied by tendonitis (enthesitis) [301-304].

One of the most important differential diagnoses of reactive arthritis is Lyme arthritis (chronic Lyme disease, Lyme disease in the late stage, stage III).

Reactive arthritis can be associated with other disease manifestations. These extra-articular symptoms in cases of reactive arthritis include urogenital symptoms, conjunctivitis, uveitis, aphthae, hyperkeratotic skin lesions in the region of the sole of the foot and the palm of the hand, nail changes as in psoriasis and genital lesions, such as balanitis.

In the diagnosis of a "reactive arthritis" anamnestic research is to be performed to determine whether there are indications of one of the above-mentioned infections. Accordingly, the following significant anamnestic considerations are important: *Chlamydia trachomatis* infection with and without symptoms, enteritis and atypical pneumonia.

Additionally, it should be remembered that arthritides are also found in *Chlamydia pneumoniae* und *Mycoplasma pneumoniae* infections and that in Chlamydioses, Yersiniosis and also in cases of *Mycoplasma pneumoniae*, the pathogen has been detected in the synovial membrane or in the articular effusions, respectively.

Using laboratory diagnostic tests (culture, serology), an existing or previous infection can be detected in 50% of the cases. Other laboratory tests, particularly inflammation markers, like the erythrocyte sedimentation rate (ESR), the C reactive protein (CRP) and leukocytosis are not relevant in cases of reactive arthritis. With regard to *Chlamydia tra-*

chomatis, pathogen detection in a urethral smear or in urine using PCR or NAATs is appropriate.

Chronic courses, *i.e.* a duration of illness exceeding 6 months, are observed in nearly 20% of the patients [305].

NSAIDs are used for treatment, but only for pain relief since they have no influence on the disease course or disease duration. In contrast, sulfasalazines [131] and TNF antibodies have certain efficacy. Antibiotic treatment is recommended in cases of acute chlamydiosis with the objective of reducing the frequency of reactive arthritis. However, studies in this direction are needed [306]. In cases of chronic reactive arthritis, the efficiency of antibiotic treatment is a matter of controversy [304,307-312].

SUMMARY OF THE CLINICAL SYMPTOMS AND THE TREATMENT OF LYME DISEASE AND CHRONIC CO-INFECTIONS

An informative overview of the different disease manifestations of Lyme disease and the significant co-infections is given in Table 10. The overview shows that there is substantial overlap in symptoms in cases of Lyme disease, bartonellosis, *Yersinia enterocolitica* and *Mycoplasma pneumoniae* infections. Additionally, *Chlamydomphila pneumoniae* also exhibits some overlap in the symptomatology with Lyme disease. *Chlamydia trachomatis* and *Campylobacter jejuni* are primarily characterized by reactive arthritis and rarely by Guillain-Barré syndrome. Only in cases with chronic Lyme disease does the antibiotic treatment (Table 11) involve the use of cephalosporins of the 3rd generation and, if necessary, of carbapenems. Otherwise, the focus is generally on tetracyclines, macrolides, to some extent on quinolones, particularly gemifloxacin, all of which, exhibit an intracellular and extracellular efficacy.

CONCLUSION

At the end of the 20th century, a number of infectious

diseases attracted the attention of medical and health policy interests. This is primarily due to the fact these diseases frequently have a chronic course. In Europe and North America, but also in many other areas of the world, these chronic diseases are caused by the following pathogens: *Borrelia burgdorferi*, *Bartonella henselae*, *Mycoplasma pneumoniae*, *Chlamydomphila pneumoniae*, *Chlamydia trachomatis*, *Yersinia enterocolitica*. In North America, HGA (Human Granulocytic Anaplasma) and Babesias are also important, whereas infections with these pathogens are a rarity in Europe. In addition, other pathogens discussed in the text are of secondary importance with regard to their frequency of occurrence. *Borrelia burgdorferi* is transmitted by ticks; in some cases this also applies to *Bartonella henselae*. The two diseases can also be simultaneously transmitted by tick bites. The remaining pathogens mentioned have other modes of transmission. — Of all the above-mentioned infectious diseases, Lyme borreliosis (*Borrelia burgdorferi*) is by far the most frequent infectious disease with a chronic course. In addition, this disease (Lyme borreliosis, Lyme disease) is the most thoroughly investigated of all the mentioned infectious diseases. On the basis of the special status of Lyme borreliosis, the other infections have been termed “coinfections” in the literature. Lyme borreliosis can be accompanied by one or more coinfections (double or multiple infections). Coinfections exacerbate the expression of the disease and hinder the therapeutic success. The symptomatology of Lyme borreliosis and the so-called coinfections exhibit high degrees of overlap. A subtle diagnostic analysis is required to account for all of the infectious diseases, which could (possibly) be present. The diagnostic and therapeutic options in cases of chronic infectious diseases are limited. This applies to Lyme borreliosis and even more for the coinfections. No adequate laboratory methods are available to the important *Bartonella henselae*, *coinfection* and there are no official guidelines available with regard to its antibiotic treatment. All of the above-mentioned pathogens are capable of intracellular localization; thus, (with the exception of

Table 10. Disease Manifestations of Chronic Lyme Disease and Chronic Co-infections (Overview)

Disease	Symptomatology									GBS	LA
	GenS	MuSk	NS	Skin	Heart	Eye	GI	UG	rA		
Lyme disease	+	+	+	+	+	+	+	+	(+)*	+	+
Bartonellosis	+	+	+	+	+	+	+	+	+	+	+
<i>Y. enterocolitica</i>	(+)	+	+	+	+	+	+	+	+	+	
<i>M. pneumoniae</i>	(+)	+	+	+	+	+	+	+	+	+	
<i>C. pneumoniae</i>			+		+				+	+	
<i>C. trachomatis</i>							+		+	+	
<i>C. jejuni</i>									+	+	

Y. enterocolitica = *Yersinia enterocolitica*; *M. pneumoniae* = *Mycoplasma pneumoniae*; *C. pneumoniae* = *Chlamydomphila pneumoniae*; *C. trachomatis* = *Chlamydia trachomatis*, *C. jejuni* = *Campylobacter jejuni*; GenS = general symptoms (fatigue, head aches, lassitude); MuSk = musculoskeletal symptoms (arthritis, arthralgias, myalgias); NS = symptoms of the nervous system (CNS, polyneuropathy, radiculopathy); Skin = skin lesions (erythema migrans, ACA in cases of Lyme disease e.g. infected skin injury); LA = lymphadenopathy; Heart = heart disease (myocarditis, cardiomyopathy, pericarditis); Eye = eye disease (uveitis, conjunctivitis, optic neuritis); GI = gastrointestinal complaints; UG = urogenital symptoms; rA = reactive arthritis; GBS = Guillain-Baré syndrome; + = positive; (+) = presumption based on general symptoms in cases of yersiniosis and *Mycoplasma pneumoniae* infection; +* = probably chronic infectious, hypothetical autoimmune origin (mimicry).

Table 11. Antibiotic Treatment of Chronic Lyme Disease and Chronic Co-infections

Disease	Antibiotic						
	Ceph3	Carbap	Tetracyc	Macrol	Quinol	TMSU	Rifa
Lyme disease	+	+	+	+	+*		
Bartonellosis			+	+	+	+	+
<i>Y. enterocolitica</i> **		+	+	+			
<i>M. pneumoniae</i>			+	+	+		
<i>C. pneumoniae</i>			+	+	+*		+
<i>C. trachomatis</i>			+	+	+*		+
<i>C. jejuni</i>				+***	+		

Ceph3 = 3rd generation cephalosporins; Carbap = carbapenems; Tetracyc = Tetracyclines; Macrol = macrolides; Quinol = quinolones; TMSU = trimethoprim and sulfamethoxazole; Rifa = rifampicin. *Gemifloxacin

* subsequent to testing; Piperacillin

** Ceph3 (if necessary + gentamycin)

*** Erythromycin

Borrelia burgdorferi) only intracellularly acting antibiotics are used. Despite this, the failure rate of the antibiotic treatment of the coinfections is high; on the other hand, with particular regard to *Bartonella henselae* the opinions on an adequate antibiotic therapy are very controversial. Since the clinical and scientific significance of these chronic infectious diseases has meanwhile been recognized, it is now imperative to develop and improve diagnostic and particularly therapeutic measures for the chronic infectious diseases.

REFERENCES

- [1] Eskow E, Rao RV, Mordechai E. Concurrent infection of the central nervous system by *Borrelia burgdorferi* and *Bartonella henselae*: evidence for a novel tick-borne disease complex. Arch Neurol 2001; 58(9): 1357-63.
- [2] Grab DJ, Nyarko E, Barat NC, Nikolskaia OV, Dumler JS. Anaplasma phagocytophilum-Borrelia burgdorferi co-infection enhances chemokine, cytokine, and matrix metalloprotease expression by human brain microvascular endothelial cells. Clin Vaccine Immunol 2007; 14(11): 1420-4.
- [3] Mitchell PD, Reed KD, Hofkes JM. Immunoserologic evidence of co-infection with *Borrelia burgdorferi*, *Babesia microti*, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota. J Clin Microbiol 1996; 34(3): 724-7.
- [4] Oleson CV, Sivalingam JJ, O'Neill BJ, Staas WE Jr. Transverse myelitis secondary to coexistent Lyme disease and babesiosis. J Spinal Cord Med 2003; 26(2): 168-71.
- [5] Owen DC. Is Lyme disease always poly microbial?--The jigsaw hypothesis. Med Hypotheses 2006; 67(4): 860-4.
- [6] Swanson SJ, Neitzel D, Reed KD, Belongia EA. Co-infections acquired from ixodes ticks. Clin Microbiol Rev 2006; 19(4): 708-27.
- [7] Thomas V, Anguita J, Barthold SW, Fikrig E. Co-infection with *Borrelia burgdorferi* and the agent of human granulocytic ehrlichiosis alters murine immune responses, pathogen burden, and severity of Lyme arthritis. Infect Immun 2001; 69(5): 3359-71.
- [8] Zeidner NS, Dolan MC, Massung R, Piesman J, Fish D. Co-infection with *Borrelia burgdorferi* and the agent of human granulocytic ehrlichiosis suppresses IL-2 and IFN gamma production and promotes an IL-4 response in C3H/HeJ mice. Parasite Immunol 2000; 22(11): 581-8.
- [9] Wormser GP, Nadelman RB, Dattwyler RJ et al. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 2000; 31 (Suppl) 1: 1-14.
- [10] Kristoferitsch W, Stanek G, Kunz C. [Double infection with early summer meningoencephalitis virus and *Borrelia burgdorferi*. [Article in German]. Dtsch Med Wochenschr 1986; 111(22): 861-4.
- [11] Hunfeld K-P. Granulocytic Ehrlichia, Babesia, and spotted fever Rickettsia. Not yet widely known tick-borne pathogens of considerable concern for humans at risk in Europe. Biotest Bull 2002; 6: 321-44.
- [12] Cadavid D, O'Neill T, Schaefer H, Pachner AR. Localization of *Borrelia burgdorferi* in the nervous system and other organs in a nonhuman primate model of Lyme disease. Lab Invest 2000; 80(7): 1043-54.
- [13] Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43(9): 1089-134.
- [14] Krause PJ, Telford SR 3rd, Spielman A, et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA 1996; 275(21): 1657-60.
- [15] Straubinger RK, Straubinger AF, Summers BA, Jacobson RH. Status of *Borrelia burgdorferi* infection after antibiotic treatment and the effects of corticosteroids: An experimental study. J Infect Dis 2000; 181(3): 1069-81.
- [16] Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin Infect Dis 2007; 45(2): 149-57.
- [17] Grab DJ, Nyarko E, Barat NC, Nikolskaia OV, Dumler JS. Anaplasma phagocytophilum-Borrelia burgdorferi co-infection enhances chemokine, cytokine, and matrix metalloprotease expression by human brain microvascular endothelial cells. Clin Vaccine Immunol 2007; 14(11): 1420-4.
- [18] Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: II. Cat-scratch disease. Pediatr Infect Dis J 1997; 16(2): 163-79.
- [19] Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin North Am 1998; 12(1): 137-55.
- [20] Wear DJ, Margileth AM, Hadfield TL, Fischer GW, Schlagel CJ, King FM. Cat scratch disease: A bacterial infection. Science 1983; 221(4618): 1403-5.
- [21] Rolain JM, Foucault C, Guieu R, La Scola B, Brouqui P, Raoult D. Bartonella quintana in human erythrocytes. Lancet 2002; 360(9328): 226-8.
- [22] Englisch CK, Wear DJ, Margileth AM, Lissner CR, Walsh GP. Cat-scratch disease. Isolation and culture of the bacterial agent. JAMA 1988; 259(9): 1347-52.
- [23] Schaller DJ. Bartonella Diagnosis and Treatment. Tampa, Florida: Hope Academic Press 2008.

- [24] Thudi KR, Kreikemeier TJ, Phillips NJ, Salvalaggio PR, Kennedy DJ, Hayashi PH. Cat scratch disease causing hepatic masses after liver transplant. *Liver Int* 2007; 27(1): 145-8.
- [25] Bhatti Z, Berenson CS. Adult systemic cat scratch disease associated with therapy for hepatitis C. *BMC Infect Dis* 2007; 7:8.
- [26] Koehler JE, Glaser CA, Tappero JW. *Rochalimaea henselae* infection. A new zoonosis with the domestic cat as reservoir. *JAMA* 1994; 271(7): 531-5.
- [27] Chomel BB, Abbott RC, Kasten RW, *et al.* *Bartonella henselae* prevalence in domestic cats in California: risk factors and association between bacteremia and antibody titers. *J Clin Microbiol* 1995; 33(9): 2445-50.
- [28] Bonatti M, Mendez J, Guerrero I, *et al.* Disseminated *Bartonella* infection following liver transplantation. *Transpl Int* 2006; 19(8): 683-7.
- [29] Vannier E, Gewurz BE, Krause PJ. Human babesiosis. *Infect Dis Clin North Am* 2008; 22(3): 469-88.
- [30] Zintl A, Mulcahy G, Skerrett HE, Taylor SM, Gray JS. *Babesia divergens*, a bovine blood parasite of veterinary and zoonotic importance. *Clin Microbiol Rev* 2003; 16(4): 622-36.
- [31] Leiby DA. Babesiosis and blood transfusion: flying under the radar. *Vox Sang* 2006; 90(3): 157-65.
- [32] Fox LM, Wingerter S, Ahmed A, *et al.* Neonatal babesiosis: case report and review of the literature. *Pediatr Infect Dis J* 2006; 25(2): 169-73.
- [33] Sethi S, Alcid D, Kesarwala H, Tolan RW Jr. Probable congenital babesiosis in infant, New Jersey, USA. *Emerging Infect Dis* 2009; 15(5): 788-91.
- [34] von Baehr V. The laboratory diagnostics of the *Borrelia* infection. *Umwelt-Magazin-Gesellschaft* 2/2009; 22:119-124.
- [35] Moriarty RA, Margileth AM. Cat-scratch disease. *Infect Dis Clin North Am* 1987; 1(3): 575-90.
- [36] Cunningham ET, Koehler JE. Ocular bartonellosis. *Am J Ophthalmol* 2000; 130(3): 340-9.
- [37] Bhatti MT, Asif R, Bhatti LB. Macular star in neuroretinitis. *Arch Neurol* 2001; 58(6): 1008-9.
- [38] Suhler EB, Lauer AK, Rosenbaum JJ. Prevalence of serologic evidence of cat scratch disease in patients with neuroretinitis. *Ophthalmology* 2000; 107(5): 871-6.
- [39] Reed JB, Scales DK, Wong MT, Lattuada CP Jr, Dolan MJ, Schwab IR. *Bartonella henselae* neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae. *Ophthalmology* 1998; 105(3): 459-66.
- [40] Marra CM. Neurologic complications of *Bartonella henselae* infection. *Curr Opin Neurol* 1995; 8(3): 164-9.
- [41] Selby G, Walker GL. Cerebral arteritis in cat-scratch disease. *Neurology* 1979; 29(10): 1413-8.
- [42] Baylor P, Garoufi A, Karpathios T, Lutz J, Mogelof J, Moseley D. Transverse myelitis in 2 patients with *Bartonella henselae* infection (cat scratch disease). *Clin Infect Dis* 2007; 45(4): e42-5.
- [43] Maman E, Bickels J, Ephros M, *et al.* Musculoskeletal manifestations of cat scratch disease. *Clin Infect Dis* 2007; 45(12): 1535-40.
- [44] Giladi M, Maman E, Paran D, *et al.* Cat-scratch disease-associated arthropathy. *Arthritis Rheum* 2005; 52(11): 3611-7.
- [45] Ben-Ami R, Ephros M, Avidor B, *et al.* Cat-scratch disease in elderly patients. *Clin Infect Dis* 2005; 41(7): 969-74.
- [46] Spach DH, Kaplan SL. Microbiology, epidemiology, clinical manifestations and diagnosis of cat scratch disease. *Up To Date*, 2008. Available at: <http://www.uptodate.com> [Accessed : 20th Sep 2010]
- [47] Jensen WA, Fall MZ, Rooney J, Kordick DL, Breitschwerdt EB. Rapid identification and differentiation of *Bartonella* species using a single-step PCR assay. *J Clin Microbiol* 2000; 38(5): 1717-22.
- [48] Fournier PE, Mainardi JL, Raoult D. Value of microimmunofluorescence for diagnosis and follow-up of *Bartonella* endocarditis. *Clin Diagn Lab Immunol* 2002; 9(4): 795-801.
- [49] Ridder GJ, Boedeker CC, Technau-Ihling K, Grunow R, Sander A. Role of cat-scratch disease in lymphadenopathy in the head and neck. *Clin Infect Dis* 2002; 35(6): 643-9.
- [50] Gilaldi M, Maman E, Paran D, *et al.* Cat-scratch disease-associated arthropathy. *Arthritis Rheum* 2005; 52(11): 3611-7.
- [51] Ridder GJ, Boedeker CC, Technau-Ihling K. Cat-scratch disease: Otolaryngologic manifestations and management. *Otolaryngol Head Neck Surg* 2005; 132(3): 353-8.
- [52] Tsujino K, Tsukahara M, Tsuneoka H, *et al.* Clinical implication of prolonged fever in children with cat scratch disease. *J Infect Chemother* 2004; 10(4): 227-33.
- [53] Methkor-Cotter E, Kletter Y, Avidor B, *et al.* Long-term serological analysis and clinical follow-up of patients with cat scratch disease. *Clin Infect Dis* 2003; 37(9): 1149-54.
- [54] Murakami K, Tsukahara M, Tsuneoka H, *et al.* Cat scratch disease: analysis of 130 seropositive cases. *J Infect Chemother* 2002; 8(4): 349-52.
- [55] Eskow E, Rao RV, Mordechai E. Concurrent infection of the central nervous system by *Borrelia burgdorferi* and *Bartonella henselae*: evidence for a novel tick-borne disease complex. *Arch Neurol* 2001; 58(9): 1357-63.
- [56] Dietrich F, Schmidgen T, Maggi RG, *et al.* Prevalence of *Bartonella henselae* and *Borrelia burgdorferi* *sensu lato* DNA in ixodes ricinus ticks in Europe. *Appl Environ Microbiol* 2010; 76(5): 1395-8.
- [57] Windsor JJ. Cat-scratch disease: epidemiology, aetiology and treatment. *Br J Biomed Sci* 2001; 58(2): 101-10.
- [58] Guptill L. Bartonellosis. *Vet Microbiol* 2010; 140(3-4): 357-59.
- [59] Cotell SL, Noskin GA. Bacillary angiomatosis. Clinical and histologic features, diagnosis, and treatment. *Arch Intern Med* 1994; 154(5): 524-8.
- [60] Pulliainen AT, Dehio C. *Bartonella henselae*: subversion of vascularendothelial cell functions by translocated bacterial effector proteins. *Int J Biochem Cell Biol* 2009; 41(3): 507-10.
- [61] Riess T, Andersson SG, Lupus A, *et al.* *Bartonella* adhesion mediates a proangiogenic host cell response. *J Exp Med* 2004; 200(10): 1267-78.
- [62] Dehio C, Meyer M, Berger J, Schwarz H, Lanz C. Interaction of *Bartonella henselae* with endothelial cells results in bacterial aggregation on the cell surface and the subsequent engulfment and internalisation of the bacterial aggregate by a unique structure, the invasome. *J Cell Sci* 1997; 100(Pt 18): 2141-54.
- [63] Kempf VA, Lebedziejewski M, Alitalo K, *et al.* Activation of hypoxia-inducible factor-1 in bacillary angiomatosis: evidence for a role of hypoxia-inducible factor-1 in bacterial infections. *Circulation* 2005; 111(8): 1054-62.
- [64] Kirby JE. *In vitro* model of *Bartonella henselae*-induced angiogenesis. *Infect Immun* 2004; 72(12): 7315-7.
- [65] Dehio C. Recent progress in understanding *Bartonella*-induced vascular proliferation. *Curr Opin Microbiol* 2003; 6(1): 61-5.
- [66] Resto-Ruiz S, Burgess A, Anderson BE. The role of the host immuneresponse in pathogenesis of *Bartonella henselae*. *DNA Cell Biol* 2003; 22(6): 431-40.
- [67] Kempf VA, Volkmann B, Schaller M, *et al.* Evidence of a leading role for VEGF in *Bartonella henselae*-induced endothelial cell proliferations. *Cell Microbiol* 2001; 3(9): 623-32.
- [68] Rolain JM, Amoux D, Parzy D, Sampol J, Raoult D. Experimental infection of human erythrocytes from alcoholic patients with *Bartonella Quintana*. *Ann NY Acad Sci* 2003; 990: 605-11.
- [69] Rolain JM, Foucault C, Guieu R, La Scola B, Brouqui P, Raoult D. *Bartonella Quintana* in human erythrocytes. *Lancet* 2002; 360(9328): 226-8.
- [70] Mursic VP, Wanner G, Reinhardt S, Wilske B, Busch U, Marget W. Formation and cultivation of *Borrelia burgdorferi* spheroplast-L-form variants. *Infection* 1996; 24(3): 218-26.
- [71] Liu NY. Randomized trial of doxycycline vs. amoxicillin/probenecid for the treatment of Lyme arthritis: treatment of non responders with iv penicillin or ceftriaxone. *Arthritis Rheum* 1989; 3(9): 46.
- [72] Kraiczy P, Skerka C, Kirschfink M, Zipfel PF, Brade V. Immune evasion of *Borrelia burgdorferi*: insufficient killing of the pathogens by complement and antibody. *Int J Med Microbiol* 2002; 291 (Suppl 33): 141-6.
- [73] Kraiczy P, Skerka C, Zipfel PF, Brade V. Complement regulator-acquiring surface proteins of *Borrelia burgdorferi*: a new protein family involved in complement resistance. *Wien Klin Wochenschr* 2002; 114(13-14): 568-73.
- [74] Mursic VP, Wanner G, Reinhardt S, Wilske B, Busch U, Marget W. Formation and cultivation of *Borrelia burgdorferi* spheroplast-L-form variants. *Infection* 1996; 24(3): 218-26.
- [75] Brorson O, Brorson SH. An *in vitro* study of the susceptibility of mobile and cystic forms of *Borrelia burgdorferi* to hydroxychloroquine. *Int Microbiol* 2002; 5(1): 25-31.

- [76] Kerkhoff FT, Rothova A. Bartonella henselae associated uveitis and HLA-B27. Br J Ophthalmol 2000; 84(10): 1125-9.
- [77] Foucault C, Brouqui P, Raoult D. Bartonella quintana characteristics and clinical management. Emerg Infect Dis 2006; 12(2): 217-23.
- [78] Relman DA. Has trench fever returned? N Engl J Med 1995; 332(7): 463-4.
- [79] Vinson JW. *In vitro* cultivation of the rickettsial agent of trench fever. Bull World Health Organ 1966; 35(2): 155-64.
- [80] Spach DH, Kanter AS, Dougherty MJ, et al. Bartonella (Rochalimaea) quintana bacteremia in inner-city patients with chronic alcoholism. N Engl J Med 1995; 332(7): 424-8.
- [81] Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998; 17(6): 447-52.
- [82] Study Team. Atovaquone plus cholestyramine in patients coinfecting with Babesia microti and Borrelia burgdorferi refractory to other treatment. Adv Ther 2006; 23(1): 1-11.
- [83] Chia JK, Nakata MM, Lami JL, Park SS, Ding JC. Azithromycin for the treatment of cat-scratch disease. Clin Infect Dis 1998; 26(1): 193-4.
- [84] Arisoy ES, Correa AG, Wagner ML, Kaplan SL. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment. Clin Infect Dis 1999; 28(4): 778-84.
- [85] Bogue CW, Wise JD, Gray GF, Edwards KM. Antibiotic therapy for cat-scratch disease? JAMA 1989; 262(6): 813-6.
- [86] Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. Antimicrob Agents Chemother 2003; 47(7): 2204-7.
- [87] Raoult D, Fournier PE, Vandenesch F, et al. Outcome and treatment of Bartonella endocarditis. Arch Intern Med 2003; 163(2): 226-30.
- [88] Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48(6): 1921-33.
- [89] Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Minireview. Recommendations for Treatment of Human Infections Caused by Bartonella Species. Antimicrob Agents Chemother 2004; 1921-33.
- [90] Pendle S, Ginn A, Iredell J. Antibicrobial susceptibility of Bartonella henselae using Etest methodology. Antimicrob Agents Chemother 2006; 761-63.
- [91] Dörbecker C, Sander A, Oberle K, Schülin-Casonato T. *In vitro* susceptibility of Bartonella species in 17 antimicrobial compounds: comparison of Etest and agar dilution. Antimicrob Agents and Chemotherapy 2006; 784-88.
- [92] Florin TA, Zaoutis TE, Zaoutis LB. Beyond cat scratch disease: widening spectrum of Bartonella henselae infection. Pediatrics 2008; 121; e1413.
- [93] Tsuneoka H, Yanagihara M, Nojima J, Ichihara K. Antimicrobial susceptibility by Etest of Bartonella henselae isolated from cats and human in Japan. J Infect Chemother 2010; 16(6): 446-8.
- [94] Conrad DA. Treatment of cat-scratch disease. J Curr Opin Pediatr 2001; 13(1): 56-9.
- [95] Sander A. Epidemiology, clinic picture und diagnostics of Bartonella infections. Institute for Medical Microbiology and Hygiene of the University of Freiburg. Antibiotika Monitor 2003. vol.3.
- [96] Sobraqués M, Maurin M, Birtels RJ, Raoult D. *In Vitro* Susceptibilities of Four Bartonella bacilliformis Strains to 30 Antibiotic Compounds. Antimicrob Agents Chemother 1999; 43(8): 2090-92.
- [97] Rolain JM, Maurin M, Raoult D. Bactericidal effect of antibiotics on Bartonella and Brucella spp.: clinical implications. J Antimicrob Chemother 2000; 46(5): 811-4.
- [98] Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992; 11(6): 474-8.
- [99] Musso D, Drancourt M, Raoult D. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. Br Soc Antimicrob Chemother 1995; 36: 101-8.
- [100] Biswas S, Maggi RC, Papich MG, Keil D, Breitschwerdt EB. Comparative activity of Pradofloxacin, Enrofloxacin, And Azithromycin against Bartonella henselae isolates collected from cats and a human. J Clin Microbiol 2010; 617-8.
- [101] Ives TJ, Manzewitsch P, Regnery RL, Butts JD, Kebede M. *In vitro* susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers. Antimicrob Agents Chemother 1997; 41(3): 578-82.
- [102] Musso D, Drancourt M, Raoult D. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. J Antimicrob Chemother 1995; 36(1): 101-8.
- [103] Kordick DL, Papich MG, Breitschwerdt EB. Efficacy of enrofloxacin or doxycycline for treatment of Bartonella henselae or Bartonella clarridgeiae infection in cats. Antimicrob Agents Chemother 1997; 41(11): 2448-55.
- [104] Kordick DL, Papich MG, Breitschwerdt EB. Efficacy of Enrofloxacin or Doxycycline for Treatment of Bartonella henselae or Bartonella clarridgeiae Infection in Cats. Antimicrob Agents Chemother 1997; 41(11): 2448-55.
- [105] Madell, GL, Bennett, JE, Dolin, R, Eds. Infectious Diseases 5th ed, Philadelphia: Churchill Livingstone 2000, p. 2007.
- [106] Myhra W, Mordhorst CH, Wang SP, et al. Clinical features of Chlamydia pneumoniae, strain TWAR, infection in Denmark 1975-1987. In: Bowie, WR, Caldwell, HD, Jones, RP (Eds), Chlamydial Infections. Cambridge Univ. Press, NY: 1980, p. 422.
- [107] Bourke SJ, Lightfoot NF. Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis. Thorax 1995; 50(Suppl 1): S43-8.
- [108] Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2010; 62(5): 1298-307.
- [109] Gérard HC, Whittum-Hudson JA, Carter JD, Hudson AP. Molecular biology of infectious agents in chronic arthritis. Rheum Dis Clin North Am 2009; 35(1): 1-19.
- [110] Carter JD, Gérard HC, Espinoza LR, et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum 2009; 60(5): 1311-6.
- [111] Fainardi E, Castellazzi M, Tamborino C, et al. Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms. J Neurovirol 2009; 15(5-6): 425-33.
- [112] Appelt DM, Roupas MR, Way DS, et al. Inhibition of apoptosis in neuronal cells infected with Chlamydia (Chlamydia) pneumoniae. BMC Neurosci 2008; 9: 13.
- [113] Contini C, Cultrera R, Seraceni S, Castellazzi M, Granieri E, Fainardi E. Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNAs associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Mult Scler 2004; 10(4): 360-9.
- [114] Gerard HC, Wang Z, Whittum-Hudson JA, et al. Cytokine and chemokine mRNA produced in synovial tissue chronically infected with Chlamydia trachomatis and C. pneumoniae. J Rheumatol 2002; 29(9): 1827-35.
- [115] De Backer J, Mak R, De Bacquer D, et al. Parameters of inflammation and infection in a community based case-control study of coronary heart disease. Atherosclerosis 2002; 160(2): 457-63.
- [116] Miklossy J, Kasas S, Zum AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation 2008; 5: 40.
- [117] Almeida OP, Lautenschlager NT. Dementia associated with infectious diseases. Int Psychogeriatr 2005; 17 (Suppl 1): S65-77.
- [118] MacDonald AB. Alzheimer's disease Braak Stage progressions: reexamined and redefined as Borrelia infection transmission through neural circuits. Med Hypotheses 2007; 68(5): 1059-64.
- [119] Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis 2010; 37(3): 534-41.
- [120] Tuuminen T, Palomäki P, Paavonen J. The use of serologic tests for the diagnosis of chlamydial infections. J Microbiol Methods 2000; 42(3): 265-79.
- [121] Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007; 44(4): 568-76.
- [122] Gaydos CA, Roblin PM, Hammerschlag MR, et al. Diagnostic utility of PCR- enzyme immunoassay, culture, and serology for

- detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. *J Clin Microbiol* 1994; 32(4): 903-5.
- [123] Vergis EN, Indorf A, File TM Jr, *et al.* Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. *Arch Intern Med* 2000; 160(9): 1294-300.
- [124] Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. *Int J Antimicrob Agents* 2004; 23(6): 533-46.
- [125] Villareal C, Whittum-Hudson JA, Hudson AP. Persistent Chlamydiae and chronic arthritis. *Arthritis Res* 2002; 4(1): 5-9.
- [126] Beutler AM, Hudson AP, Whittum-Hudson JA, *et al.* Chlamydia trachomatis Can Persist in Joint Tissue After Antibiotic Treatment in Chronic Reiter's Syndrome / Reactive Arthritis. *J Clin Rheumatol* 1997; 3(3): 125-130.
- [127] Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. *MMWR Recomm Rep* 2006; 55(RR-11): 1-94.
- [128] Quinn TC, Welsh L, Lentz A, *et al.* Diagnosis by AMPLICOR PCR of Chlamydia trachomatis infection in urine samples from women and men attending sexually transmitted disease clinics. *J Clin Microbiol* 1996; 34(6): 1401-6.
- [129] Chernesky MA, Lee H, Schachter J, *et al.* Diagnosis of Chlamydia trachomatis urethral infection in symptomatic and asymptomatic men by testing first-void urine in a ligase chain reaction assay. *J Infect Dis* 1994; 170(5): 1308-11.
- [130] Cook RL, Hutchinson SL, Ostergaard L, Braithwaite RS, Ness RB. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoea. *Ann Intern Med* 2005; 142(11): 914-25.
- [131] Clegg DO, Reda DJ, Weisman MH, *et al.* Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. *Arthritis Rheum* 1996; 39(12): 2021-7.
- [132] Flagg SD, Meador R, Hsia E, Kitumnuaypong T, Schumacher HR Jr. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. *Arthritis Rheum* 2005; 53(4): 613-7.
- [133] Ostroff S. Yersinia as an emerging infection: epidemiologic aspects of Yersiniosis. *Contrib Microbiol Immunol* 1995; 13: 5-10.
- [134] Portnoy DA, Martinez RJ. Role of a plasmid in the pathogenicity of Yersinia species. *Curr Top Microbiol Immunol* 1985; 118: 29-51.
- [135] Iriarte M, Sory MP, Boland A, *et al.* YaeA, a protein involved in control of Yop release and in translocation of Yersinia Yop effectors. *EMBO J* 1998; 17(7): 1907-18.
- [136] Sarker MR, Sory MP, Boyd AP, Iriarte M, Cornelis GR. LcrG is required for efficient translocation of Yersinia Yop effector proteins into eukaryotic cells. *Infect Immun* 1998; 66(6): 2976-9.
- [137] Boland A, Cornelis GR. Role of YopP in suppression of tumor necrosis factor alpha release by macrophages during Yersinia infection. *Infect Immun* 1998; 66(5): 1878-84.
- [138] Tacket CO, Narain JP, Sattin R, *et al.* A multistate outbreak of infections caused by Yersinia enterocolitica transmitted by pasteurized milk. *JAMA* 1984; 251(4): 483-6.
- [139] Ostroff SM, Kapperud G, Lassen J, Aasen S, Tauxe RV. Clinical features of sporadic Yersinia enterocolitica infections in Norway. *J Infect Dis* 1992; 166(4): 812-7.
- [140] Tauxe RV, Vandepitte J, Wauters G, *et al.* Yersinia enterocolitica infections and pork: the missing link. *Lancet* 1987; 1(8542): 1129-32.
- [141] Tacket CO, Davis BR, Carter GP, Randolph JF, Cohen ML. Yersinia enterocolitica pharyngitis. *Ann Intern Med* 1983; 99(1): 40-2.
- [142] Cover TL, Aber RC. Yersinia enterocolitica. *N Engl J Med* 1989; 321(1): 16-24.
- [143] Black RE, Slome S. Yersinia enterocolitica. *Infect Dis Clin North Am* 1988; 2(3): 625-41.
- [144] Reed RP, Robins-Browne RM, Williams ML. Yersinia enterocolitica peritonitis. *Clin Infect Dis* 1997; 25(6): 1468-9.
- [145] Blinkhorn RJ Jr, Marino JA. Lateral pharyngeal abscess due to Yersinia enterocolitica. *Am J Med* 1988; 85(6): 851-2.
- [146] Krogstad P, Mendelman PM, Miller VL, *et al.* Clinical and microbiologic characteristics of cutaneous infection with Yersinia enterocolitica. *J Infect Dis* 1992; 165(4): 740-3.
- [147] Crowe M, Ashford K, Ispahani P. Clinical features and antibiotic treatment of septic arthritis and osteomyelitis due to Yersinia enterocolitica. *J Infect Microbiol* 1996; 45(4): 302-9.
- [148] Kellogg CM, Tarakji EA, Smith M, Brown PD. Bacteremia and suppurative lymphadenitis due to Yersinia enterocolitica in a neutropenic patient who prepared chitterlings. *Clin Infect Dis* 1995; 21(1): 236-7.
- [149] Saebø A, Lassen J. Yersinia enterocolitica: an inducer of chronic inflammation. *Int J Tissue React* 1994; 16(2): 51-7.
- [150] Saebø A, Lassen J. Acute and chronic pancreatic disease associated with Yersinia enterocolitica infection: a Norwegian 10-year follow-up study of 458 hospitalized patients. *J Intern Med* 1992; 231 (5): 537-41.
- [151] Saebø A, Lassen J. Acute and chronic gastrointestinal manifestations associated with Yersinia enterocolitica infection. A Norwegian 10-year follow-up study on 458 hospitalized patients. *Ann Surg* 1992; 215(3): 250-5.
- [152] Lindholm H, Visakorpi R. Late complications after a Yersinia enterocolitica epidemic: a follow up study. *Ann Rheum Dis* 1991; 50(10): 694-6.
- [153] Saebø A, Lassen J. A survey of acute and chronic disease associated with Yersinia enterocolitica infection. A Norwegian 10-year follow-up study on 458 hospitalized patients. *Scand J Infect Dis* 1991; 23(5): 517-27.
- [154] Fordham JN, Maitra S. Post-yersinial arthritis in Cleveland, England. *Ann Rheum Dis* 1989; 48(2): 139-42.
- [155] Saebø A, Vik E, Lange OJ, Matuszkiewicz L. Inflammatory bowel disease associated with Yersinia enterocolitica O:3 infection. *Eur J Intern Med* 2005; 16(3): 176-82.
- [156] van der Heijden IM, Res PC, Wilbrink B, *et al.* Yersinia enterocolitica: a cause of chronic polyarthritis. *Clin Infect Dis* 1997; 25(4): 831-7.
- [157] Granfors K, Jalkanen S, von Essen R, *et al.* Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. *N Engl J Med* 1989; 320(4): 216-21.
- [158] Granfors K, Merilähti-Palo R, Luukkainen R, *et al.* Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. *Arthritis Rheum* 1998; 41(5): 855-62.
- [159] Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patient with Yersinia arthritis. *Arthritis Rheum* 1988; 31(4): 533-7.
- [160] Braun J, Tuszewski M, Eggens U, *et al.* Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. I. Screening of synovial samples of patients with spondyloarthropathies and other arthritides. *J Rheumatol* 1997; 24(6): 1092-100.
- [161] Hoogkamp-Korstanje JA, de Koning J, Heesemann J. Persistence of Yersinia enterocolitica in man. *Infection* 1988; 16(2): 81-5.
- [162] Bottone EJ. Yersinia enterocolitica: the charisma continues. *Clin Microbiol Rev* 1997; 10(2): 257-76.
- [163] Martin RE, Bates JH. Atypical pneumonia. *Infect Dis Clin North Am* 1991; 5(3): 585-601.
- [164] Frydén A, Bengtsson A, Foberg U, *et al.* Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study. *BMJ* 1990; 301(6764): 1299-302.
- [165] Mansel JK, Rosenow EC 3rd, Smith TF, Martin JW Jr. Mycoplasma pneumoniae pneumonia. *Chest* 1989; 95(3): 639-46.
- [166] Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review. *Clin Infect Dis* 1993; 17 (Suppl 1): S52-7.
- [167] Daxboeck F. Mycoplasma pneumoniae central nervous system infections. *Curr Opin Neurol* 2006; 19(4): 374-8.
- [168] Bitnun A, Ford-Jones E, Blaser S, Richardson S. Mycoplasma pneumoniae encephalitis. *Semin Pediatr Infect Dis* 2003; 14(2): 96-107.
- [169] Smith R, Eviatar L. Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature. *Clin Pediatr (Phila)* 2000; 39(4): 195-201.
- [170] Tsiodras S, Kelesidis T, Kelesidis I, Voumbourakis K, Giamarellou H. Mycoplasma pneumoniae-associated myelitis: a comprehensive review. *Eur J Neurol* 2006; 13(2): 112-24.
- [171] Chaudhry R, Nisar N, Malhotra P, Kumar A, Chauhan VS. Polymerase chain reaction confirmed Mycoplasma pneumoniae

- arthritis: a case report. *Indian J Pathol Microbiol* 2003; 46(3): 433-6.
- [172] Vitullo BB, O'Regan S, de Chadarevian JP, Kaplan BS. Mycoplasma pneumoniae associated with acute glomerulonephritis. *Nephron* 1978; 21(5): 284-8.
- [173] Weinstein O, Shneck M, Levy J, Lifshitz T. Bilateral acute anterior uveitis as a presenting symptom of Mycoplasma pneumoniae infection. *Can J Ophthalmol* 2006; 41(5): 594-5.
- [174] Yashar SS, Yashar B, Epstein E, Viani RM. Uveitis associated with Mycoplasma pneumoniae meningitis. *Acta Ophthalmol Scand* 2001; 79(1): 100-1.
- [175] Fusco C, Bonini E, Soncini G, Frattini D, Giovannini S, Della Giustina E. Transient basal ganglia and thalamic involvement following Mycoplasma pneumoniae infection associated with antiganglioside antibodies. *J Child Neurol* 2010; 25(8): 1029-33.
- [176] Ashtekar CS, Jaspan T, Thomas D, Weston V, Gayatri NA, Whitehouse WB. Acute bilateral thalamic necrosis in a child with Mycoplasma pneumoniae. *Dev Med Child Neurol* 2003; 45(9): 634-7.
- [177] Hsing J, Welgampola M, Kieman MC. Reversible myeloradiculopathy due to Mycoplasma pneumoniae. *J Clin Neurosci* 2007; 14(1): 61-4.
- [178] Tsioufas S, Kelesidis I, Kelesidis T, Stamboulis E, Gimarellou H. Central nervous system manifestations of Mycoplasma pneumoniae infections. *J Infect* 2005; 51(5): 343-54.
- [179] Timitilli A, Di Rocco M, Nattero G, Tacchella A, Giacchino R. Unusual manifestations of infections due to Mycoplasma pneumoniae in children. *Infez Med* 2004; 12(2): 113-7.
- [180] Goebels N, Helmchen C, Abele-Horn M, Gasser T, Pfister HW. Extensive myelitis associated with Mycoplasma pneumoniae infection: magnetic resonance imaging and clinical long-term follow-up. *J Neurol* 2001; 248(3): 204-8.
- [181] Rabay-Chacar H, Rizkallah E, Hakimeh NI, Khoury L, Merhej MT. Neurological complications associated with Mycoplasma pneumoniae infection. A case report. *J Med Liban* 2000; 48(2): 108-11.
- [182] Abele-Horn M, Franck W, Busch U, Nitschko H, Roos R, Heesemann J. Transverse myelitis associated with Mycoplasma pneumoniae infection. *Clin Infect Dis* 1998; 26(4): 909-12.
- [183] Francis DA, Brown A, Miller DH, Wiles CM, Bennett ED, Leigh N. MRI appearances of the CNS manifestations of Mycoplasma pneumoniae: a report of two cases. *J Neurol* 1988; 235(7): 441-3.
- [184] MacFarlane PI, Miller V. Transverse myelitis associated with Mycoplasma pneumoniae infection. *Arch Dis Child* 1984; 59(1): 80-2.
- [185] Cotter FE, Bainbridge D, Newland AC. Neurological deficit associated with Mycoplasma pneumoniae reversed by plasma exchange. *Br Med J (Clin Res Ed)* 1983; 286(6358): 22.
- [186] Nicholson G. Transverse myelitis complicating Mycoplasma pneumoniae infection. *Postgrad Med J* 1977; 53(616): 86-7.
- [187] Hely MA, Williamson PM, Terenty TR. Neurological complications of Mycoplasma pneumoniae infection. *Clin Exp Neurol* 1984; 20: 153-60.
- [188] Gorthi SP, Kapoor L, Chaudhry R, et al. Guillain-Barré syndrome: association with Campylobacter jejuni and Mycoplasma pneumoniae infections in India. *Natl Med J India* 2006; 19(3): 137-9.
- [189] Manteau C, Liest JM, Caillon J, et al. Acute severe spinal cord dysfunction in a child with meningitis: Streptococcus pneumoniae and Mycoplasma pneumoniae co-infection. *Acta Paediatr* 2005; 94(9): 1339-41.
- [190] Pfausler B, Engelhardt K, Kampfl A, Spiss H, Tafemer E, Schmutzhard E. Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature. *Eur J Neurol* 2002; 9(1): 93-6.
- [191] Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FG. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. *Neurology* 2000; 54(3): 620-5.
- [192] Maida E, Kristoferitsch W. Cerebrospinal fluid findings in mycoplasma pneumoniae infections with neurological complications. *Acta Neurol Scand* 1982; 65(5): 524-38.
- [193] Bayer AS, Galpin JE, Theofilopoulos AN, Guze LB. Neurological disease associated with Mycoplasma pneumoniae pneumonitis: demonstration of viable Mycoplasma pneumoniae in cerebrospinal fluid and blood by radioisotopic and immunofluorescent tissue culture techniques. *Ann Intern Med* 1981; 94(1): 15-20.
- [194] Socan M, Ravnik I, Bencina D, Dovc P, Zakotnik B, Jazbec J. Neurological symptoms in patients whose cerebrospinal fluid is culture- and/or polymerase chain reaction-positive for Mycoplasma pneumoniae. *Clin Infect Dis* 2001; 32(2): E31-5.
- [195] Dionisio D, Valassina M, Mata S, et al. Encephalitis caused directly by Mycoplasma pneumoniae. *Scand J Infect Dis* 1999; 31(5): 506-9.
- [196] Narita M, Matsuzono Y, Itakura O, Togashi T, Kikuta H. Survey of mycoplasmal bacteremia detected in children by polymerase chain reaction. *Clin Infect Dis* 1996; 23(3): 522-5.
- [197] Thomas NH, Collins JE, Robb SA, Robinson RO. Mycoplasma pneumoniae infection and neurological disease. *Arch Dis Child* 1993; 69(5): 573-6.
- [198] Carstensen H, Nilsson KO. Neurological complications associated with Mycoplasma pneumoniae infection in children. *Neuropediatrics* 1987; 18(1): 57-8.
- [199] Foy HM, Nolan CM, Allan ID. Epidemiologic aspects of M. pneumoniae disease complications: a review. *Yale J Biol Med* 1983; 56(5-6): 469-73.
- [200] Mardh PA, Ursing B, Lind K. Persistent cerebellar symptoms after infection with Mycoplasma pneumoniae. *Scand J Infect Dis* 1975; 7(2): 157-60.
- [201] Trad S, Ghosn J, Dormont D, Stankoff B, Bricaire F, Caumes E. Nuclear bilateral Bell's palsy and ataxia associated with Mycoplasma pneumoniae pulmonary infection. *J Med Microbiol* 2005; 54(Pt4): 417-9.
- [202] Völter C, Helms J, Weissbrich B, Rieckmann P, Abele-Horn M. Frequent detection of Mycoplasma pneumoniae in Bell's palsy. *Eur Arch Otorhinolaryngol* 2004; 261(7): 400-4.
- [203] Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review. *Clin Infect Dis* 1993; 17 (Suppl) 1:S52-7.
- [204] Assaad F, Gispén R, Kleemola M, Syrucek L, Esteves K. Neurological diseases associated with viral and Mycoplasma pneumoniae infections. *Bull World Health Organ* 1980; 58(2): 297-311.
- [205] Lind K, Zoffmann H, Larsen SO, Jessen O. Mycoplasma pneumoniae infection associated with affection of the central nervous system. *Acta Med Scand* 1979; 205(4): 325-32.
- [206] Fink CG, Sillis M, Read SJ, Butler L, Pike M. Neurological disease associated with Mycoplasma pneumoniae infection. PCR evidence against a direct invasive mechanism. *Clin Mol Pathol* 1995; 48(1): M51-4.
- [207] Di Maria A, Ruberto G, Redaelli C, Gualtieri G. Anterior uveitis associated with Mycoplasma pneumoniae pneumonia: a case report. *Acta Ophthalmol Scand* 1999; 77(3): 349-50.
- [208] Said MH, Layani MP, Colon S, Faraji G, Gilastre C, Cochat P. Mycoplasma pneumoniae-associated nephritis in children. *Pediatr Nephrol* 1999; 13(1): 39-44.
- [209] Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. *J Antimicrob Chemother* 1990; 25 (Suppl) A: 123-6.
- [210] File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. *Antimicrob Agents Chemother* 1997; 41(9): 1965-72.
- [211] Maeda K, Markowitz N, Hawley RC, Ristic M, Cox D, McDade JE. Human infection with Ehrlichia canis, a leukocytic rickettsia. *N Engl J Med* 1987; 316(14): 853-6.
- [212] Chen SM, Dumler JS, Bakken JS, Walker DH. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. *J Clin Microbiol* 1994; 32(3): 589-95.
- [213] Nadelman RB, Horowitz HW, Hsieh TC, et al. Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis. *N Engl J Med* 1997; 337(1): 27-30.
- [214] Schwartz I, Fish D, Daniels TJ. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease. *N Engl J Med* 1997; 337(1): 49-50.
- [215] Horowitz HW, Kilchevsky E, Haber S, et al. Perinatal transmission of the agent of human granulocytic ehrlichiosis. *N Engl J Med* 1998; 339(6): 375-8.

- [216] Bakken JS, Dumler S. Human granulocytic anaplasmosis. *Infect Dis Clin North Am* 2008; 22(3): 433-48.
- [217] Bakken JS, Krueth JK, Lund T, Malkovitch D, Asanovich K, Dumler JS. Exposure to deer blood may be a cause of human granulocytic ehrlichiosis. *Clin Infect Dis* 1996; 23(1): 198.
- [218] Krause PJ, Wormser GP. Nosocomial transmission of human granulocytic anaplasmosis? *JAMA* 2008; 300(19): 2308-9.
- [219] Levin ML, Fish D. Acquisition of co-infection and simultaneous transmission of *Borrelia burgdorferi* and *Ehrlichia phagocytophila* by *Ixodes scapularis* ticks. *Infect Immun* 2000; 68(4): 2183-6.
- [220] Maeda K, Markowitz N, Hawley RC, Ristic M, Cox D, McDade JE. Human infection with *Ehrlichia canis*, a leukocytic rickettsia. *N Engl J Med* 1987; 316(14): 853-6.
- [221] Chen SM, Dumler JS, Bakken JS, Walkder DH. Identification of agranulocytotropic ehrlichia species as the etiologic agent of human disease. *J Clin Microbiol* 1994; 32(3): 589-95.
- [222] Demma LJ, Holman RC, McQuiston JH, Krebs JW, Swerdlow DL. Epidemiology of human ehrlichiosis and anaplasmosis in the United States, 2001-2001. *Am J Trop Med Hyg* 2005; 73(2): 400-9.
- [223] Björnsdóttir A, Wittesjö B, Berglund J, Massung RF, Eliasson I. Human granulocytic ehrlichiosis as a common cause of tick-associated fever in Southeast Sweden: report from a prospective clinical study. *Scand J Infect Dis* 2002; 34(3): 187-91.
- [224] Stanczak J, Gabre RM, Kruminis-Lozowska W, Racewicz M, Kubica-Biemat B. *Ixodes ricinus* as a vector of *Borrelia burgdorferi sensu lato*, *Anaplasma phagocytophilum* and *Babesia microti* in urban and suburban forests. *Ann Agric Environ Med* 2004; 11(1): 109-14.
- [225] Fingerle V, Munderloh UG, Liegl G, Wilske B. Coexistence of ehrlichiae of the phagocytophila group with *Borrelia burgdorferi* in *Ixodes ricinus* from Southern Germany. *Med Microbiol Immunol* 1999; 188(3): 145-9.
- [226] Oehme R, Hartelt K, Backe H, Brockmann S, Kimming P. Foci of tick-borne diseases in southwest Germany. *Int J Med Microbiol* 2002; 291 (Suppl) 33: 22-9.
- [227] Schouls LM, Van De Pol I, Rijpkema SG, Schot CS. Detection and identification of *Ehrlichia*, *Borrelia burgdorferi sensu lato*, and *Bartonella* species in Dutch *Ixodes ricinus* ticks. *J Clin Microbiol* 1999; 37(7): 2215-22.
- [228] Baumgarten B, Harrer TH, Rölinghoff M, Bogdan C. Prevalence of human granulocytic Ehrlichiosis in *Ixodes* ticks from Southern Germany: Evidence for genetic heterogeneity. VIII International Conference on Lyme disease and other Emerging Tick-Borne Diseases, Munich, 1999 (abstract).
- [229] Hildebrandt A, Schmidt KH, Wilske B, Dom W, Straube E, Fingerle V. Prevalence of four species of *Borrelia burgdorferi sensu lato* and co-infection with *Anaplasma phagocytophila* in *Ixodes ricinus* ticks in central Germany. *Eur J Clin Microbiol Infect Dis* 2003; 22(6): 364-7.
- [230] Schaubert EM, Gertz SJ, Maple WT, Ostfeld RS. Co-infection of blacklegged ticks (*Acari: Ixodidae*) in Dutchess County, New York, with the agents of Lyme disease and human granulocytic ehrlichiosis. *J Med Entomol* 1998; 35(5): 901-3.
- [231] Schwartz I, Fish D, Daniels TJ. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease. *N Engl J Med* 1997; 337(1): 49-50.
- [232] Bakken JS, Krueth J, Tilden RL, Dumler JS, Kristiansen BE. Serological evidence of human granulocytic ehrlichiosis in Norway. *Eur J Microbiol Infect Dis* 1996; 15(10): 829-32.
- [233] Hermanowska-Szpakowicz T, Skotarczak B, Kondrusik M, et al. Detecting DNAs of *Anaplasma phagocytophilum* and *Babesia* in the blood of patients suspected of Lyme disease. *Ann Agric Environ Med* 2004; 11(2): 351-4.
- [234] Pusterla N, Weber R, Wolfensberger C, et al. Serological evidence of human granulocytic ehrlichiosis in Switzerland. *Eur J Clin Microbiol Infect Dis* 1998; 17(3): 207-9.
- [235] Magnarelli LA, Dumler JS, Anderson JF, Johnson RC, Fikring E. Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera. *J Clin Microbiol* 1995; 33(11): 3054-7.
- [236] Bakken JS, Dumler S. Human granulocytic anaplasmosis. *Infect Dis Clin North Am* 2008; 22(3): 433-48.
- [237] Roland WE, McDonald G, Caldwell CW, Everett ED. Ehrlichiosis – a cause of prolonged fever. *Clin Infect Dis* 1995; 20(4): 821-5.
- [238] Aguero-Rosenfeld ME, Horowitz HW, Wormser GP, et al. Human granulocytic ehrlichiosis: A case series from a medical center in New York State. *Ann Intern Med* 1996; 125(11): 904-8.
- [239] Bakken JS, Dumler JS. Clinical diagnosis and treatment of human granulocytotropic anaplasmosis. *Ann N Y Acad Sci* 2006; 1078: 236-47.
- [240] Dumler JS, Bakken JS. Ehrlichial diseases of humans: emerging tick-borne infections. *Clin Infect Dis* 1995; 20(5): 1102-10.
- [241] Dawson JE, Fishbein DB, Eng TR, Redus MA, Green NR. Diagnosis of human ehrlichiosis with the indirect fluorescent antibody test: kinetics and specificity. *J Infect Dis* 1990; 162(1): 91-5.
- [242] Brouqui P, Bacellar F, Baranton G, et al. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. *Clin Microbiol Infect* 2004; 10(12): 1108-32.
- [243] Bakken JS, Haller I, Riddell D, Walls JJ, Dumler JS. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. *Clin Infect Dis* 2002; 34(1): 22-7.
- [244] Bakken JS, Dumler JS. Ehrlichiosis and anaplasmosis. *Infect Med* 2004; 21: 433.
- [245] Paddock CD, Childs JE. *Ehrlichia chaffeensis*: a prototypical emerging pathogen. *Clin Microbiol Rev* 2003; 16(1): 37-64.
- [246] Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. *JAMA* 1996; 275(3): 199-205.
- [247] Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. *Clin Infect Dis* 2001; 32(6): 862-70.
- [248] Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis – United States: a practical guide for physicians and other health-care and public health professionals. *MMWR Recomm Rep* 2006; 55(RR-4): 1-27.
- [249] Standaert SM, Yu T, Scott MA, et al. Primary isolation of *Ehrlichia chaffeensis* from patients with febrile illnesses: clinical and molecular characteristics. *J Infect Dis* 2000; 181(3): 1082-8.
- [250] Felek S, Unver A, Stich RW, Rikihisa Y. Sensitive detection of *Ehrlichia chaffeensis* in cell culture, blood, and tick specimens by reverse transcription-PCR. *J Clin Microbiol* 2001; 39(2): 460-3.
- [251] Walls JJ, Caturegli P, Bakken JS, Asanovich KM, Dumler JS. Improved sensitivity of PCR for diagnosis of human granulocytic ehrlichiosis using *pank1* genes of *Ehrlichia phagocytophila*-group ehrlichiae. *J Clin Microbiol* 2000; 38(1): 354-6.
- [252] Meer-Scherrer L, Adelson M, Mordechai E, Lottaz B, Tilton R. *Babesia microti* infection in Europe. *Curr Microbiol* 1996; 48(6): 435-7.
- [253] Mitchell PD, Reed KD, Hofkes JM. Immunoserologic evidence of co-infection with *Borrelia burgdorferi*, *Babesia microti*, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota. *J Clin Microbiol* 1996; 34(3): 724-7.
- [254] Oleson CV, Sivalingam JJ, O'Neill BJ, Staas WE Jr. Transverse myelitis secondary to coexistent Lyme disease and babesiosis. *J Spinal Cord Med* 2003; 26(2): 168-71.
- [255] Shoemaker RC, Hudnell HK, House DE, Van Kempen A, Pakes GE, COL40155 Study Team. Atovaquone plus cholestyramine in patients coinfecting with *Babesia microti* and *Borrelia burgdorferi* refractory to other treatment. *Adv Ther* 2006; 23(1): 1-11.
- [256] Skotarczak B, Wodecka B, Cichocka A. Coexistence DNA of *Borrelia burgdorferi sensu lato* and *Babesia microti* in *Ixodes ricinus* ticks from north-western Poland. *Ann Agric Environ Med* 2002; 9(1): 25-8.
- [257] Skotarczak B, Rymaszewska A, Wodecka B, Sawczuk M. Molecular evidence of co-infection of *Borrelia burgdorferi sensu lato*, human granulocytic ehrlichiosis agent, and *Babesia microti* in ticks from northwestern Poland. *J Parasitol* 2003; 89(1): 194-6.
- [258] Halos L, Jamal T, Maillard R, et al. Evidence of *Bartonella* sp. in questing adult and nymphal *Ixodes ricinus* ticks from France and co-infection with *Borrelia burgdorferi sensu lato* and *Babesia* sp. *Vet Res* 2005; 36(1): 79-87.
- [259] Schwartz I, Fish D, Daniels TJ. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease. *N Engl J Med* 1997; 337(1): 49-50.
- [260] Hermanowska-Szpakowicz T, Skotarczak B, Kondrusik M, et al. Detecting DNAs of *Anaplasma phagocytophilum* and *Babesia* in the blood of patients suspected of Lyme disease. *Ann Agric Environ Med* 2004; 11(2): 351-4.

- [261] Arnez M, Luznik-Bufon T, Avsic-Zupanc T, *et al.* Causes of febrile illness after a tick bite in Slovenian children. *Pediatr Infect Dis* 2003; 22(12): 1078-83.
- [262] Stricker RB, Gaito A, Harris NS, Burrascano JJ. Co-infection in patients with Lyme disease: how big a risk? *Clin Infect Dis* 2003; 37(9): 1277-8.
- [263] Krause PJ, Telford SR 3rd, Spielman A, *et al.* Concurrent Lyme disease and babesiosis. *JAMA* 1996; 275(21): 1657-60.
- [264] Wang TJ, Liang MH, Shangha O, *et al.* Coexposure to *Borrelia burgdorferi* and *Babesia microti* does not worsen the long-term outcome of Lyme disease. *Clin Infect Dis* 2000; 31(5): 1149-54.
- [265] Krause PJ, McKay K, Thompson CA, *et al.* Disease-specific diagnosis of coinfecting tickborne zoonosis: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. *Clin Infect Dis* 2002; 34(9): 1184-91.
- [266] Hatcher JC, Greenberg PD, Antique J, Jimenez-Lucho VE. Severe babesiosis in Long Island: review of 34 cases and their complications. *Clin Infect Dis* 2001; 32(8): 1117-25.
- [267] Krause PJ, Telford SR 3rd, Spielman A, *et al.* Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. *JAMA* 1996; 275(21): 1657-60.
- [268] Reubush TK 2nd, Cassaday PB, Marsh HJ, *et al.* Human babesiosis on Nantucket Island. Clinical features. *Ann Intern Med* 1977; 86(1): 6-9.
- [269] White DJ, Talarico J, Chang HG, Birkhead GS, Heimberger T, Morse DL. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. *Arch Intern Med* 1998; 158(19): 2149-54.
- [270] Krause PJ, Ryan R, Telford S 3rd, Persing D, Spielman A. Efficacy of immunoglobulin M serodiagnostic test for rapid diagnosis of acute babesiosis. *J Clin Microbiol* 1996; 34(8): 2014-6.
- [271] Krause PJ, Telford SR 3rd, Ryan R, *et al.* Diagnosis of babesiosis: evaluation of a serologic test for the detection of *Babesia microti* antibody. *J Infect Dis* 1994; 169(4): 923-6.
- [272] Vannier E, Gewurz BE, Krause PJ, *et al.* Human babesiosis. *Infect Dis Clin North Am* 2008; 22: 469.
- [273] Shaked Y, Samra Y. Q fever meningoencephalitis associated with bilateral abducens nerve paralysis, bilateral optic neuritis and abnormal cerebrospinal fluid findings. *Infection* 1989; 17(6): 394-5.
- [274] Brooks RG, Licitra CM, Peacock MG. Encephalitis caused by *Coxiella burnetii*. *Ann Neurol* 1986; 20(1): 91-3.
- [275] Kofteridis DP, Mazokopakis EE, Tselentis Y, Gikas A. Neurological complications of acute Q fever infection. *Eur J Epidemiol* 2004; 19(11): 1051-4.
- [276] Walid MS, Ajjan M, Ulm AJ. Subacute Transverse myelitis with Lyme profile dissociation. *Ger Med Sci* 2008; 6: Doc04.
- [277] Bernit E, Pouget J, Janbon F *et al.* Neurological involvement in acute Q fever: a report of 29 cases and review of the literature. *Arch Intern Med* 2002; 162(6): 693-700.
- [278] Bonetti B, Monaco S, Ferrari S, Tezzon F, Rizzuto N. Demyelinating polyradiculoneuritis following *Coxiella burnetii* infection (Q fever). *Ital J Neurol Sci* 1991; 12(4): 415-7.
- [279] Nikkari S, Roivainen A, Hannonen P, *et al.* Persistence of parvovirus B19 in synovial fluid and bone marrow. *Ann Rheum Dis* 1995; 54(7): 597-600.
- [280] Kühl U, Pauschinger M, Seeborg B, *et al.* Viral persistence in the myocardium is associated with progressive cardiac dysfunction. *Circulation* 2005; 112(13): 1965-70.
- [281] Tschöpe C, Bock CT, Kasner M, *et al.* High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. *Circulation* 2005; 111(7): 879-86.
- [282] Donoso Mantke O, Nitsche A, Meyer R, Klingel K, Niedrig M. Analysing myocardial tissue from explanted hearts of heart transplant recipients and multi-organ donors for the presence of parvovirus B19 DNA. *J Clin Virol* 2004; 31(1): 32-9.
- [283] Schenk T, Enders M, Pollak S, Hahn R, Huzly D. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. *J Clin Microbiol* 2009; 47(1): 106-10.
- [284] Lindblom A, Isa A, Norbeck O, *et al.* Slow clearance of human parvovirus B19 viremia following acute infection. *Clin Infect Dis* 2005; 41(8): 1201-3.
- [285] Lowry SM, Brent LH, Menaldino S, Kerr JR. A case of persistent parvovirus B19 infection with bilateral cartilaginous and ligamentous damage to the wrists. *Clin Infect Dis* 2005; 41(4): e42-4.
- [286] Friedman CR, Neimann J, Wegener HC, Tauxe RV. Epidemiology of *Campylobacter jejuni* infections in the United States and other industrialized nations. In: Nachamkin I, *Campylobacter*, 2nd ed, Blaser MJ, Eds, Washington DC: ASM Press 2000; p. 121.
- [287] Whitehouse CA, Balbo PB, Pesci EC, Cottle DL, Mirabito PM, Pickett CL. *Campylobacter jejuni* cytolethal distending toxin causes a G2-phase cell cycle block. *Infect Immun* 1998; 66(5): 1934-40.
- [288] Pickett CL, Pesci EC, Cottle DL, Russell G, Erdam AN, Zeytin H. Prevalence of cytolethal distending toxin production in *Campylobacter jejuni* and relatedness of *Campylobacter* sp. cdtB gene. *Infect Immun* 1996; 64(6): 2070-8.
- [289] Skirrow MB, Blaser MJ. *Campylobacter jejuni*. In: Blaser MJ, Smith PD, Ravdin JI, *et al.* Eds. Infections of the gastrointestinal tract, 2nd ed, Philadelphia: 2002; Lippincott Williams and Wilkins, p. 719.
- [290] Hannu T, Kauppi M, Tuomala M, Laaksonen I, Klemets P, Kuusi M. Reactive arthritis following an outbreak of *Campylobacter jejuni* infection. *J Rheumatol* 2004; 31(3): 528-30.
- [291] Garg AX, Pope JE, Thiessen-Philbrook H, Clark WF, Ouimet J, Walkerton Health Study Investigators. Arthritis risk after acute bacterial gastroenteritis. *Rheumatology (Oxford)* 2008; 47(2): 200-4.
- [292] Townes JM, Deodhar AA, Laines ES, *et al.* Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study. *Ann Rheum Dis* 2008; 67(12): 1689-96.
- [293] Shenker BJ, Besack D, McKay T, Pankoski L, Zekavat A, Demuth DR. Induction of cell cycle arrest in lymphocytes by *Actinobacillus actinomycetemcomitans* cytolethal distending toxin requires three subunits for maximum activity. *J Immunol* 2005; 174(4): 2228-34.
- [294] Sorvillo FJ, Lieb LE, Waterman SH. Incidence of campylobacteriosis among patients with AIDS in Los Angeles County. *J Acquir Immune Defic Syndr* 1991; 4(6): 598-602.
- [295] Melamed I, Bujanover Y, Igra YS, Schwartz D, Zakuth V, Spirer Z. *Campylobacter* enteritis in normal and immunodeficient children. *Am J Dis Child* 1983; 137(8): 752-3.
- [296] Taylor DE, Chang N. *In vitro* susceptibilities of *Campylobacter jejuni* and *Campylobacter coli* to azithromycin and erythromycin. *Antimicrob Agents Chemother* 1991; 35(9): 1917-8.
- [297] Gaunt PD, Piddock LJ. Ciprofloxacin resistant *Campylobacter* spp. in humans: an epidemiological and laboratory study. *J Antimicrob Chemother* 1996; 37(4): 747-57.
- [298] Lariviere LA, Gaudreau CL, Turgeon FF. Susceptibility of clinical isolates of *Campylobacter jejuni* to twenty-five antimicrobial agents. *J Antimicrob Chemother* 1986; 18(6): 681-5.
- [299] Ahvonen P, Sievers K, Aho K. Arthritis associated with *Yersinia enterocolitica* infection. *Acta Rheumatol Scand* 1969; 15(3): 232-53.
- [300] Panush RS, Wallace DJ, Dorff RE, Engleman EP. Retraction of the suggestion to use the term "Reiter's syndrome" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. *Arthritis Rheum* 2007; 56(2): 693-4.
- [301] Keynan Y, Rimar D. Reactive arthritis - the appropriate name. *Isr Med Assoc J* 2008; 10(4): 256-8.
- [302] Hannu T, Inman R, Granfors K, Leirisalo-Repo M. Reactive arthritis or post-infectious arthritis? *Best Pract Res Clin Rheumatol* 2006; 20(3): 419-33.
- [303] Braun J, Kingsley G, van der Heijde D, Sieper J. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. *J Rheumatol* 2000; 27(9): 2185-92.
- [304] Leirisalo-Repo M. Reactive arthritis. *Scand J Rheumatol* 2005; 34(4): 251-9.
- [305] Leirisalo-Repo M, Sieper J. Reactive arthritis: epidemiology, clinical features and treatment. In: Weisman MH, van der Heijde D, Reveille JD, Eds. *Ankylosing spondylitis and the spondyloarthropathies*. Philadelphia: Mosby Elsevier 2006; pp. 53-64.
- [306] Yu DT. Pathogenesis of reactive arthritis. *Intern Med* 1999; 38(2): 97-101.

- [307] Kvien TK, Gaston JS, Bardin T, *et al.* Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. *Ann Rheum Dis* 2004; 63(9): 1113-9.
- [308] Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, *et al.* Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. *Ann Rheum Dis* 2003; 62(9): 880-4.
- [309] Lauhio A, Leirisalo-Repo M, Lähdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. *Arthritis Rheum* 1991; 34(1): 6-14.
- [310] Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, *et al.* Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. *Ann Rheum Dis* 2000; 59(7): 565-70.
- [311] Laasila N, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. *Ann Rheum Dis* 2003; 62(7): 655-8.
- [312] Putschky N, Pott HG, Kuipers JG, Zeidler H, Hammer M, Wollenhaupt J. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. *Ann Rheum Dis* 2006; 65(11): 1521-4

Received: April 28, 2012

Revised: June 22, 2012

Accepted: July 02, 2012

© Walter Berghoff; Licensee *Bentham Open*.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.